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4TIIVISTELMÄ, Finnish summary
D-vitamiini ylläpitää normaalia luun kasvua ja uudistumista koko elämän ajan. Suomessa, kuten
monissa muissakin länsimaissa, väestön D-vitamiinitilanne on riittämätön – talvisin osalla jopa
puutteellinen. Tässä väitöskirjassa on tutkittu, lisääkö D-vitamiini luumassan kertymistä kasvuiässä,
ja ylläpitäkö D-vitamiini luuston tasapainoista aineenvaihduntaa aikuisiällä. Nämä vaikutukset
saattavat ehkäisi osteoporoosin kehittymistä eri ikäkausina.
Väitöskirjatyössä tutkittiin erisuuruisten D-vitamiinilisäysten vaikutuksia kolmessa eri ikäryhmässä,
jotka olivat 11-12 -vuotiaat tytöt (N=228), 21-49 -vuotiaat miehet (N=54) ja 65-85 -vuotiaat naiset
(N=52). Tutkittavat satunnaistettiin ryhmiin, jotka nauttivat joko lumevalmistetta tai 5-20 µg D3-
vitamiinia vitamiinilisänä. Tutkimukset olivat kaksoissokkoutettuja. Tutkimuksen aikana
tutkittavilta otettiin paastoveri- ja virtsanäytteitä. Lisäksi he täyttivät tutkimuslomakkeen
taustatietojen kartoittamiseksi sekä frekvenssikyselylomakkeen kalsiumin ja D-vitamiinin saannin
selvittämiseksi. Tyttöjen luunmineraalitiheys (BMD) mitattiin DXA–laitteella ja miesten
volumetrinen luuntiheys pQCT-menetelmällä. Näytteistä määritettiin mm. seerumin 25-hydroksi-D-
vitamiinin (=S-25-OHD), lisäkilpirauhashormonin (=S-PTH) ja luun aineenvaihduntaa kuvaavien
merkkiaineiden pitoisuuksia.
Murrosikäisten tyttöjen poikkileikkaustutkimuksessa S-25-OHD- ja luun muodostusmerkkiaineen
pitoisuudet vaihtelivat kuukausien välillä; suurimmat pitoisuudet mitattiin syyskuussa ja pienimmät
maaliskuussa, mikä kuvastaa vuodenaikaisvaihtelua. Vastaava vaihtelu havaittiin lannerangan ja
reisiluun BMD:ssä. D-vitamiinilisäyksellä oli myönteinen vaikutus tyttöjen luumassan
lisääntymiseen. Suurin D-vitamiinilisä (10 µg/vrk) lisäsi luumassaa 17.2% enemmän reisiluussa ja
12.5% enemmän lannerangassa verrattuna lumevalmistetta nauttivien tyttöjen vastaaviin tuloksiin,
mutta tulos riippui hoitomyöntyvyydestä. D-vitamiinin vaikutus luustoon välittyi vähentyneen luun
hajotuksen kautta. Tutkimustuloksiin perustuen riittävä D-vitamiinin saanti murrosikäisille tytöille
on 15 µg/vrk.
D-vitamiinilisän vaikutus 65-85 -vuotiaiden naisten S-25-OHD-pitoisuuteen vakioitui kuudessa
viikossa annoksen ollessa 5-20 µg/vrk. Näillä D-vitamiiniannoksilla ei saavutettu tavoiteltavaa S-
25-OHD-pitoisuutta, joka on 80 nmol/l. Arvioimme, että 60 nmol/l -pitoisuuden, jota esiintyy
kesäisin tämän ikäryhmän suomalaisilla, tämän ikäryhmän naiset saavuttaisivat 24 µg:n
päivittäisellä D-vitamiinin saannilla.
5Terveillä miehillä havaittiin vuodenaikaisvaihtelu S-25-OHD- ja S-PTH-pitoisuudessa sekä luun
hajotusta kuvaavassa merkkiainepitoisuudessa. Toisaalta vaihtelua ei havaittu radiuksen
volumetrisessä luuntiheydessä eikä luun muodostusmerkkiaineen pitoisuudessa.
Vuodenaikaisvaihtelu estettiin 17 µg:n päivittäisellä D-vitamiinin saannilla, mutta tämän ei havaittu
vaikuttavan radiuksen luuntiheyteen kuusi kuukautta kestävän tutkimuksen aikana.
Yhteenvetona todetaan, että D-vitamiinin saanti on edelleenkin riittämätöntä tutkimusten
kohderyhmillä. Tämä näkyy S-25-OHD- ja PTH-pitoisuuden sekä luunaineenvaihduntaa kuvaavien
merkkiaineiden vuodenaikaisvaihteluna, mikä on haitallista luuston hyvinvoinnille. D-vitamiinin
saantia tulisi lisätä, jotta vähintäänkin riittävä D-vitamiinitilanne (S-25-OHD>50 nmol/l) tai
mahdollisesti jopa tavoiteltava D-vitaminitilanne (S-25-OHD?80 nmol/l) saavutettaisiin. Jotta D-
vitamiinin saannin lisääminen olisi kaikissa ikäryhmissä mahdollista, on suunniteltava nykyistä
enemmän D-vitamiinilla täydennettyjä elintarvikkeita.
6ABSTRACT
Vitamin D is required for normal bone growth and maintenance of the skeleton throughout life. In
Finland, like in many other Western countries, the population suffers from inadequate or deficient
vitamin D status, especially during winter, which is thought to increase the risk of osteoporosis.
New strategies to prevent osteoporosis are actively being sought. The main objective of this thesis
was to determine whether vitamin D is feasible in the primary prevention of osteoporosis; does it
affect bone mineral accrual during the growth period? A second goal was to ascertain whether
seasonal variation in calcitropic hormones affects bone remodelling, and to elucidate the vitamin D
intake needed to overcome this variation in different age groups.
The subjects were healthy, free-living representatives of their respected age groups: 11- to 12-year-
old girls (N=228), 21- to 49-year-old men (N=54) and 65- to85-year-old women (N=52). Subjects
participated in an intervention trial in which they were randomly assigned to a group receiving 0, 5,
10 or 20 µg of vitamin D as a supplement. All studies were performed double-blinded. Fasting
blood and urine samples were collected together with data about, for instance, dietary intake of
calcium and vitamin D and physical activity. In two studies bone mineral density (BMD) of subjects
was measured at enrolment and at the end of the study. Laboratory analysis consisted of
measurements of serum 25-hydroxyvitamin D (S-25-OHD), parathyroid hormone (S-PTH) and
bone remodelling markers.
Differences among months were observed in calcitropic hormones, bone formation marker, and
BMD of the femur and vertebra in a cross-sectional study of early and mid pubertal girls, thus
predicting seasonal variation. Vitamin D supplementation increased bone mineral accrual dose-
dependently both in the femur and the vertebra of adolescent girls. Bone mineral accrual was 17.2%
higher in the femur and 12.5% higher in the vertebra with 10 µg of vitamin D than with placebo, but
the effect depended on compliance. The effect of vitamin D on bone was mediated through
decreased resorption. Based on the results, a total intake of 15 µg/d appears to be sufficient for
adolescent girls.
The effect of vitamin D supplementation (5-20 µg/d) on S-25-OHD concentration of elderly women
reached a plateau within six weeks. A concentration of 80 nmol/l, which is considered optimal, was
not achieved with these dosages. We estimated that a concentration of 60 nmol/l, which is typically
seen during summer in Finland, requires a total intake of 24 µg/d of vitamin D in elderly women.
7Seasonal variation in calcitropic hormones and bone resorption marker, but not in volumetric BMD
of the radius or bone formation marker, was noted in healthy men in a prospective study. Vitamin D
supplementation increased S-25-OHD, inhibited winter elevation of PTH and decreased bone
formation marker, but did not affect BMD during this 6 month study. Adequate intake to avoid the
season-related changes was calculated to be 17 µg/d.
In summary, vitamin D intake remains inadequate among the target groups of this thesis, as
reflected by seasonal variation in calcitropic hormones and bone metabolism. Dietary intake of
vitamin D should be increased to achieve at least an adequate vitamin D status (S-25-OHD>50
nmol/l) and possibly an optimal vitamin D status (S-25-OHD>80 nmol/l) throughout the year. This
could be accomplished by introducing new vitamin D-fortified foods to the market.
8ABBREVIATIONS
1,25(OH)2D 1,25-dihydroxyvitamin D, calcitriol
24,25(OH)2D 24,25-dihydroxyvitamin D
25-OHD 25-hydroxyvitamin D, calcidiol
AI adequate intake
ALTM all laboratory trimmed mean
ANCOVA analysis of covariance
ANOVA analysis of variance
BA bone area
BALP bone specific alkaline phosphatase
BAP bone specific alkaline phosphatase activity
BMC bone mineral content
BMD bone mineral density
BMI bone mass index
CaBP calcium binding protein
CB compliance based
CBA competitive protein binding assay
CSA cross-sectional area
CT computed tomography
CV% coefficient for variation percentage
D2 ergocalciferol
D3 cholecalciferol
DBP vitamin D binding protein
DEQAS vitamin D external quality assessment scheme
DPyr deoxypyridinoline
DR dose-response
DXA dual-energy x-ray absorptiometry
EIA enzymeimmunoassay
FFQ food frequency questionnaire
HPLC high-performance liquid chromatography
HSD honestly significant difference
IGF-1 insulin-like growth factor 1
IT intention to treat
IU international unit
LSD least significant difference
NOAEL no observed adverse effect level
9NTX cross-linked N-telopeptides of type I collagen
OC osteocalcin
PICP carboxy-terminal propeptide of type I procollagen
PINP amino-terminal propeptide  of type I procollagen
PBM peak bone mass
pQCT peripheral quantitative computed tomography
PTH parathyroid hormone
Pyr pyridinoline
RCT randomized controlled trial
RIA radioimmunoassay
S- serum
TRACP tartrate-resistant acid phosphatase
U- urinary
UL upper limit
vBMD volumetric bone mineral density
VDR vitamin D receptor
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1. INTRODUCTION
Although 60-80% of bone mass is determined by genes, lifestyle factors, such as nutrition and
physical activity, and possibly their interaction play a crucial role in bone mass accrual during
growth, maintaining stable bone turnover in adulthood and preventing bone loss with age. With the
exception of lung cancer, osteoporosis causes more disability than any other chronic disease
(Johnell & Kanis 2006). Within the next 30 years, the incidence of osteoporosis is estimated to
increase threefold due to ageing of the population; an inactive lifestyle and unhealthy food patterns
contribute to this increase (Kannus et al. 1999).
The primary focus of this thesis is on supporting bone health with adequate dietary intake of
vitamin D. The relationship between vitamin D and bone was described in 18th century when
ultraviolet light and sunlight were discovered as cures for rickets in both England and Leiden. Since
the 18th century cod liver oil has been used as a medicine for rickets, although the antirachitic factor
in cod liver oil was not recognized until 1920 (Mellanby 1919). In Finland, the prevalence of rickets
among newborn and small children decreased dramatically from 1950s with systematic vitamin D
supplementation (Hallman et al. 1964). In present studies the final outcome variables are not as
distinct and obvious as were the clinical symptoms of rickets, but they describe bone health in a
modern way.
The dietary guidelines of vitamin D for children aged under 3 years have changed over the years,
from 60-100 µg in 1940 to 10 µg in 1996 (Ala-Houhala 2002). Initially, recommended doses were
too high, causing toxic effects as hypercalcaemia and kidney stones. The currently recommended
intake of 7.5-10 µg is safe for all age groups. The safety aspect was carefully considered by the
Scientific Committee on Food in 2002 before announcing NOAEL (no observed adverse effect
level) and UL (upper limit) for vitamin D intake. Long-term vitamin D intake in children aged less
than 11 years should not exceed 25 µg and in adults 50 µg No other nutrient has as narrow limit for
adequate and safe intakes (Scientific Committee on Food 2002) although they are challenged now
and then (e.g Vieth et al. 2001, Heaney et al. 2003a).
Vitamin D is required for normal skeletal growth. In addition, it is agreed that vitamin D
insufficiency enhances the development of osteoporosis. Nowadays, the focus on the prevention of
12
osteoporosis by maximizing bone mass accrual during the growth phase (primary prevention),
which might begin as early as in the uterus. Vitamin D therapy is also feasible and cost-effective at
other stage of life (secondary and tertiary prevention). These aspects are discussed in this work and
novel evidence is provided to support the old hypothesis once again – vitamin D is supporting bone
health in all age groups.
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2. REVIEW OF THE LITERATURE
2.1 Vitamin D
2.1.1 Sources of vitamin D
Globally, the most important vitamin D source is sunlight UVB (290-315 nm) radiation, which
induces photosynthesis of vitamin D in the skin (Webb et al. 1989). The energy of the radiation
converts the provitamin 7-dehydrocholesterol to previtamin D. The amount of previtamin D is
regulated by transforming it to photoisomers tachysterol and lumisterol, which are abundant when
the sunlight exposure is prolonged (MacLaughlin et al. 1982). After sun exposure, previtamin D is
converted to cholecalciferol (D3), which is catalysed by skin temperature. Vitamin D3 is then
translocated from epidermal to dermal circulation. If isomers are not reconverted to previtamin D,
they are sloughed off during natural skin turnover.
Skin regulates vitamin D3 production by tanning. After an erytremal dose, which expresses time to
reach equilibrium in previtamin D3 production, takes 20 min in white skin. Pigmented skin does not
absorb all UVB radiation, and the time required for an erytremal dose is 3-6 longer (Lo et al. 1986).
An equivalent dose to 10 ?g is achieved by exposing 5% of skin area to sunlight for 10-15 min
(Davie et al. 1982). By comparing oral dosing of vitamin D with sun exposure, a full body exposure
to sunlight for 10-15 min is estimated to enhance vitamin D synthesis up to 218-250 ?g (Vieth
1999). Sun protection filter tells how much longer a person can stay in the sun compared with
unprotected skin. Sun screen with sun protection filter and clothing decreases vitamin D3
production. In addition, 7-dehydrochlesterol concentration in the skin decreases during normal
ageing (MacLaughlin & Holick 1985).
Although the sun is globally the most important vitamin D source, food is also relevant in countries
located north of 60o. In these areas, sunlight exposure is limited during winter, and virtually no
UVB radiation exists for 6 months, or the angle of the radiation is insufficient to produce vitamin D
in the skin (Webb et al. 1989).
Traditionally, fish, liver and egg yolk are considered as major food sources of natural vitamin D3
Minor concentration of vitamin D3 can also be isolated from meat and milk, but the content depends
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on the feed and sun exposure of the animals providing these products. Fish in dark-watered lakes
and oceans contain less vitamin D3 than fish in clear waters, probably due to more generous vitamin
D synthesis in clear waters (Mattila et al. 1995). In addition, farmed fish have lower vitamin D3
content than wild fish (Lu et al. 2007). Plant-origin vitamin D is called ergocalciferol (D2). Some
wild-grown mushrooms (Outila et al. 1999) and algae contain D2. In industry, vitamin D2 is formed
by the photolysis of specific algae, while D3 is extracted from fish liver oils or as a by-product of
lamb wool (Trang et al. 1998).
In the human body both forms of vitamin D are metabolized, but vitamin D2 is thought to have
lower bioavailability than vitamin D3 (Armas et al. 2004). Vitamin D2 increases S-25-OHD
concentration less than D3 (Trang et al. 1998, Armas et al. 2004).In the United States, the vitamin D
added to foods, is mainly D2 which is the major form found in supplements as well. On the other
hand, in Europe, D3 is more abundantly used in industry and in fortified foods. D3 is claimed to be
more photo- and temperature-stable than D2 (Holick 1998, Trang et al. 1998). In this text, vitamin D
is used as synonym for vitamin D3.
Because of relatively few vitamin D sources in the diet and the growing awareness of the negative
impact of low vitamin D status in the general population, the number of vitamin D-fortified
products or foods on the market has increased. Good fortification practice requires evaluating
different possible carriers for vitamin D. In Europe and the US, milk products, juices, spreads,
cereals, oils and bread are favoured fortification targets (Lu et al. 2007).
In Finland, margarines and spreads have been fortified since 1940 with vitamin D (7.5 µg/100 ml).
In addition, the vitamin D content of low-fat and fat-free milk was recovered to the natural level
found in unprocessed milk (0.08 µg/100 ml) in the early 1980s. Lamberg-Allardt et al. 2001
observed that the dietary intakes of vitamin D were insufficient, as roughly 30 % of the healthy
adult population suffered from vitamin D deficiency (S-25-OHD? 25 nmol/l) during wintertime and
over half of the population had inadequate vitamin D status (S-25-OHD? 40 nmol/l). Based on the
simulated calculations suggested by Lamberg-Allardt et al. (2003), the Ministry of Social Affairs
and Health expanded the fortification of liquid milk products to 0.5 µg/100 g including milk, sour
milk and yoghurt, excluding organic products and increased the fortification of margarines and
spreads to 10 µg/100 g. Although the fortification is voluntary, most dairy companies began
supplementing milk and sour milk products, but fortification of yoghurts has proceeded slowly.
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2.1.2 Vitamin D metabolism
Dietary vitamin D is absorbed nearly 100% in the ileum. It is transported with other fats in
chylomicrons via lymphatic vessels that empty the contents to the thoracic duct. In the liver,
vitamin D undergoes its first hydroxylation to 25-carbon and forms 25-hydroxyvitamin D (25-
OHD), which is the most abundant vitamin D metabolite in the body (Fig. 1). Part of the ingested
vitamin D2 is also transformed to D3, but 25-hydroxylase is capable of hydroxylating D2 as well.
The activity of liver 25-hydroxylase is not regulated (Brown et al. 1999) when the body stores of
25-OHD are within the normal range (20-120 nmol/l), but certainly vitamin D, 25-OHD and
1,25(OH)2D can control its activity by negative feedback, at least in in vitro studies.
The major metabolic site of vitamin D is the liver. The activity of the circulating 25-OHD molecule
depends mainly on the amount of vitamin D binding protein (DBP) also known as Gc globulin, a
specific transporter of vitamin D in the circulation. The normal serum concentration of DBP varies
from 4 to 6 µmol/l depending on the phenotype of Gc (Lauridsen et al. 2005). Vitamin D
originating from the skin is bound to DBP when entering the circulation. Excess vitamin D is stored
in fat and muscle tissue, and small amounts in the liver. The stores are mobilized when the
concentration of circulating 25-OHD decreases. DBP has a higher affinity for 25-OHD than for
1,25(OH)2D or vitamin D, and this affinity favours the release of the active metabolite into the
blood. The half-life of 25-OHD varies between 20 and 30 days, differing among Gc phenotypes
(Lauridsen et al. 2005).
To become metabolically active, vitamin D needs to be 1-hydroxylated, which systemically occurs
in the kidney. The concentration of the active metabolite, 1,25(OH)2D, is strictly regulated by
negative feedback of 1,25(OH)2D concentration, parathyroid hormone (PTH), growth hormone,
estrogens and serum phosphate and the lifespan of calcitriol is extremely short (from 4 to 6 hours)
(Clements et al. 1992). Yet most tissues contain 1-?-hydroxylases, enabling the local production of
calcitriol (e.g. Brown 1999), which may partly explain why calcidiol concentration correlates with
PTH (Vieth et al. 2003) and bone mineral density (BMD) (Outila et al. 2001, Välimäki et al. 2004,
Bischoff-Ferrari et al. 2004a).
Free 1,25(OH)2D enters all cells due to its fat solubility. The active metabolite binds to its specific
receptor, VDR, in the nucleus and activates genes alone as a homodimer or in heterodimer form
with retinol receptor superfamily members. There are alternative pathways in vitamin D metabolism
that are related to further hydroxylation of 23-, 24- or 26-carbons (Brown 1999). Although some
16
metabolites have their own specific activity, like 24,25(OH) 2D in the fibrous tissue, the
hydroxylation steps mainly increase the water solubility of the molecule and induce the metabolic
inactivation and secretion of the body. Calcitronic acid is the final form of vitamin D, which is
secreted in urine.
Figure 1. Simplified schematic of vitamin D metabolites.
2.1.3 Functions in the body
The 25-OHD-DBP complex of enters cells via a receptor-mediated endocytic pathway (Willnow &
Nukjaer 2005). This pathway includes the release of 25-OHD from the complex as well as the
recycling of the transmembrane proteins cubilin and megalin (Willnow & Nukjaer 2005). After the
conversion of 25-OHD to 1,25(OH)2D, this binds to VDR and affects the production of proteins.
The main function of vitamin D in cells is to increase calcium binding proteins (CaBP) in the
cytoplasma. CaBP can modulate calcium fluxes in the cell, thus regulating cell proliferation and
differentiation. Because VDRs are found in most cells of the body, the biological responses to
vitamin D vary according to cell.
One of the main functions of vitamin D is calcium absorption from the intestine. In a repleted
vitamin D status, the amount of CaBP in mucosal cells is increased and active calcium transport is
optimally working (DeLuca 1979). The threshold for maximum calcium absorption capability has
been suggested to be 80 nmol/l (Heaney et al. 2003b). In a vitamin D depleted state, calcium
absorption occurs only with passive diffusion, which is hardly adequate to meet the needs of the
body.
Vitamin D acts in the bone by increasing the production of osteocalcin, a matrix protein. In
addition, it regulates bone resorption, and thus, maintains bone turnover. Over the years, additional
ERGOCALCI-
FEROL, D2
CHOLECALCI-
FEROL, D3
25-OHD 1,25(OH)2D
LIVER KIDNEY
OTHER
TISSUES
PTH
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target organs have been recognized, including muscles (Ritz et al. 1980, Bischoff-Ferrari et al.
2004b). Epidemiological studies have revealed a relationship between deficient vitamin D status
and different chronic diseases such as type I diabetes, multiple sclerosis, osteoarthritis, prostate and
colon cancer, vascular calcification and coronary heart disease (Zittermann 2003, Bischoff-Ferrari
et al. 2006). Moreover, some evidence suggests that immune response (Cannell et al. 2006),
depression (Berk et al. 2007) and infertility (Panda et al. 2001) are also related to vitamin D
insufficiency.
2.1.4 Vitamin D status
The most abundant vitamin D metabolite in the body, serum 25-OHD, is generally used to reflect
the vitamin D status of the body. Other markers of calcium metabolism, such as S-Ca, U-Ca, S-PTH
and S-1,25(OH)2D, are used alongside S-25-OHD, as they are tightly involved in the clinical status
of vitamin D (Need et al. 2000). While no international consensus has been reached regarding
reference ranges to describe each status, some common guidelines are recognized (Table 1).
Table 1. Categories of vitamin D status adopted from Lips (2004) and Dawson-Hughes et al. (2005)
+ increase, 0 no effect, - decrease
In vitamin D deficiency, the S-25-OHD concentration is generally considered to be below 20-25
nmol/l (Need et al. 2000, Lips 2004). Vitamin D deficiency is related to rickets and osteomalacia
among children and adults, respectively, both of which feature low mineralization of bones.
Subclinical vitamin D deficiency or vitamin D insufficiency, also called vitamin D inadequacy, is
characterized by serum levels of 25-40 nmol/l (Need et al. 2000) or 25-50 nmol/l (Lips 2004). In
vitamin D insufficiency, the vitamin D stores of the body are depleted, the concentration of PTH is
increased by at least 15% and 1,25(OH)2D is also elevated (Lips 2004).
S-25-OHD, nmol/l Status S-iPTH 1,25(OH)2D BMD
<25 Deficiency + 15 % - 30 % ++ -
Osteomalacia, rickets
25-49.9 Inadequate/
Insufficient
+ 15 % + -
50-79.9 Adequate /
Sufficient
0 0 0
? 80 Optimal 0 0 +
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Adequate vitamin D status is characterized by S-25-OHD concentration above 40 nmol/l (Need et
al. 2000) or above 50 nmol/l (Lips 2004, Rizzoli et al. 2008), and normal concentrations of PTH
and 1,25(OH)2D. For general bone health (Dawson-Hughes et al. 2005) as well as for the prevention
of certain chronic diseases (Zittermann 2003, Bischoff-Ferrari et al. 2006), the optimal 25-OHD
concentration has been speculated to be around 80 nmol/l, although some consider this to be an
overestimate, more suitable for risk groups than for the normal population (Rizzoli et al. 2008).
Changes in vitamin D status are mediated through PTH, which is the main regulator of calcium
metabolism (Maver and Davis 2001) (Fig. 2). In inadequate vitamin D status, the decreased
absorption of calcium from the small intestine affects serum calcium intermittently, stimulating the
parathyroid glands to secrete PTH. PTH activates 1-?-hydroxylases in the kidney to produce more
calcitriol and further accelerates vitamin D metabolism. Serum calcium concentration is corrected
with increased absorption from the intestine. During the next step the amount of 25-OHD is
insufficient to form calcitriol; this state is known as vitamin D deficiency. Because calcium
absorption can no longer increase, calcium is mobilized from the skeleton by resorption. The
clinical features of vitamin D deficiency are osteomalacia and rickets.
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Figure 2 illustrates the development of vitamin D deficiency as described by Maver & Davies
(2001).
2.1.4.1 Methods for assessing S-25-OHD
At least six different methods are used world wide to measure s-25-OHD concentration. These
include high-performance liquid chromatography (HPLC), radioimmunoassay (RIA),
enzymeimmunoassay (EIA), competitive protein binding assay (CBA) and chemiluminescence
assay. Although the HPLC method is considered the gold standard for measuring 25-OHD, the
number of laboratories using it is declining (Carter et al. 2004). This could be due to its complexity,
the pre-treatment of samples necessary and the poor recovery. Its advantages comprise separation of
25-OHD2 and 25-OHD3 and a rather small bias compared with other analytical methods. The most
frequently used method is RIA, in which 125I isotope is preferred (Carter et al. 2007). Advantages of
RIA are its good precision and ease of use. On the other hand, handling of radioactive isotopes
requires its own places in the laboratory and produces hazardous waste which is disadvantageous.
Sometimes RIA has difficulties in recognizing 25-OHD2, which is commonly used in dietary
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supplements in the US (Carter et al. 2004). Increasing numbers of laboratories have chosen EIA
because of its ease and rapid results. Its performance is not the best, as it tends to overestimate,
especially higher concentrations, and the results are likely affected by the sample matrix (Carter et
al. 2004).
Despite the good precision of the method the results are not necessarily true. Interlaboratory
comparisons are justified to ensure validity of the measurement. The International Vitamin D
External Quality Assessment Scheme (DEQAS) was created for this purpose. DEQAS delivers
serum samples to each participating laboratory and sums up the results. This way all laboratory
trimmed mean (ALTM) values are provided to facilitate comparisons of different methods. ALTM
is the mean value for all results within three standard deviations of the mean. Recently, Dawson-
Hughes et al. (2005) proposed that standardized values for S-25-OHD should be reported in
scientific articles.
2.1.5 Dietary guidelines and current intakes in Finland
In 2004, the National Nutrition Council (2005) increased the recommendation for vitamin D intake
from 5 to 7.5 µg a day for individuals aged 3-60 years of age. For children under 3 years and
persons over 60 years including pregnant and lactating women as well as other risk groups the
recommended intake is 10 µg. The dietary guidelines in Finland are based on the Nordic Nutrition
Recommendations (Nordic Council of Ministers 2004). In the United States, the Institute of
Medicine has set only an adequate intake (AI) for vitamin D, as scarce evidence exists for a
recommended daily allowance. The AI for groups 0-50 years, 51-70 years and >71 years is 5 µg, 10
µg and 15 µg, respectively (Institute of Medicine 1997). Recommended nutrient intakes published
by the World Health Organization are in accord with the guidelines of the Institute of Medicine.
In the Findiet 2002 Study, the mean dietary intake of vitamin D among 25- to 64-year-old men and
women was 5.8 µg/d and 3.8 µg/d, respectively (National Public Health Institute 2003). The mean
energy-standardized daily intake of vitamin D was 0.6 µg/MJ. As mentioned earlier, vitamin D
fortification of food stuff expanded in 2003. The current recommended intake (National Nutrition
Council 2005) is achieved if the diet contains three glasses of fortified milk (0.5 µg /100 ml),
fortified spreads (10 µg /100 g) and at least two portions of fish dishes a week (Table 2). Vitamin D
intakes were examined in a follow-up study on vitamin D status in the Finnish population
(Lamberg-Allard et al. 2006). The dietary intake of vitamin D was found to increase on average 2.3
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µg/d between 2002 and 2004, of which 1.8 µg originated from fortified milk products and 0.3 µg
from spreads (Lamberg-Allardt et al. 2006). The use of vitamin D-containing supplements was
beneficial, but despite the supplements the total intakes were still inadequate among 4- to 6-year-old
girls, 14- to 17-year-old girls and 27- to 35-year-old men and women.
Table 2. Vitamin D content of selected food product
Food product µg of vitamin D per 100 g of product1
Salmon 9.8
Tuna 1.8
Whitefish 22.0
Herring 18.0
Coalfish 1.5
Cod 7.5
Milk 0.5
Margarine 9.2
Egg 2.2
Liver 0.8
Poultry 0.7-1.0
Meat 0.2-0.5
Cantharellus cibarius 12.8
Boletus edulis 2.9
1 Source: National Food Database Fineli®, National Public Health Institute
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2.2 Bone
2.2.1 Bone growth at puberty
Typically, growth slows down during late childhood and a clear acceleration occurs at puberty.
Pubertal growth consists of three phases: slow acceleration at prepuberty, growth spurt for two
years at midpuberty and normalization and termination of growth at late puberty. Genetic, hormonal
and nutritional factors modify the tempo and timing of growth. Improved health and nutritional
status over the decades has advanced sexual maturation in industrialized countries. Body fat content
is one of the most common modulators of pubertal development (Marshall & Tanner 1969, Aloia et
al. 1995).
Pubertal growth starts earlier in girls than in boys. The evaluation of pubertal development is based
on external characteristics of height increment, pubic hair and breast/penis (Table 3). The growth
spurt, in which the height increment exceeds 6 cm per year, peaks at the age of 12 years in girls and
at 14 years in boys (Boot et al. 1997, Bailey et al. 2000). In both genders, peak height velocity is
observed at pubertal stage 3 (Mølgaard et al. 1999). The greater height increment and longer
duration of the growth period are thought to be the reasons why boys reach a larger skeletal size
than girls (Bailey et al. 2000, Heaney et al. 2000).
In late childhood and prepuberty, the height of long bones, i.e the femur, tibia and forearm,
increases dramatically (Boot et al. 1997). Mineralization occurs in the growth plate cartilage at the
epiphyses of long bones, thus increasing the length of the bone. Fig. 3 illustrates the modelling of
the radius involving both bone formation and bone resorption. Typically, during puberty the size of
the trunk increases, comprising vertebral growth and widening of the pelvis (Bass et al. 1999).
During growth the size and the shape of the skeleton changes constantly. Heaney et al. (2000) stated
that the size of the bone increases first, producing collagen-rich bone. Hydroxyapatite crystals are
later added. The lag between collagen-rich bone and mineralization among girls is longer than
among boys mainly because the increase of bone size goes together with an increase of lean body
mass. This mechanostat theory links the bone development to the strain caused by muscle
contraction (Frost et al. 1998, Fricke & Schoenau 2007). In boys, with greater lean body mass
accrual (Mølgaard et al. 1999), the muscles surround the bones and apply pressure to unmineralized
bone more extensively during growth, leading to quicker mineral accrual. Among girls, this lag
between increased bone size and mineralization is from 3 to6 months. Thus, bone strength decreases
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transiently, and this could create a problem. An increasing rate of fractures occurs during this highly
intensive growth period that is typically known for the peak height velocity (Bailey et al. 1989).
Table 3. Puberty development in girls based on Tanner stage (modified from Marshall & Tanner
1969).
Tanner stage Description
1 Height: At basal rate
Breast: Papilla elevation
Pubic hair: Unpigmented, villus hair only
2 Height: Increased rate, over 5 cm annually
Breast: Buds palpable and areolae enlarge
Pubic hair: Some coarse, pigmented hair, mainly on labia
3 Height: Increases at peak rate, 8 cm per year
Breast: Elevation of breast contour, areolae enlarge
Pubic hair: Dark, coarse, curly hair spreads over mons pubis
Axillary hair develops
4 Height: Increased rate
Breast: Areolae forms secondary mound on the breast
Pubic hair: Adult-like hair, but not spread
First menstrual bleeding, menarche
5 Height: Increases modestly
Breast: Adult breast contour
Pubic hair: Adult distribution of hair
Menses quite regular
Figure 3. Bone growth and modelling occur at the epiphyses of long bones. Here the situation in
the radius over an 8- to 11-month perioid is presented (adapted from Rauch et al. 2001a).
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Bone mineral accrual continues after the cessation of axial (longitudinal) growth (Bailey et al.
2000). In late adolescence, 80-90% of the adult peak bone mass (PBM) is accrued (Matkovic et al.
1994, Bonjour et al. 1994). PBM is reached before the age of 16 years in girls and around 18 years
in boys in most skeletal sites except of the cortices of long bones (Bonjour et al. 1991, Theintz et al.
1992, Lorentzon et al. 2005), although individual and racial differences exist. Many of the
discrepancies related to the achievement of PBM are derived from different measurements (Wren et
al. 2007). Axial growth ceases as the growth plates in long bones are closed by oestrogens in both
genders.
2.2.2 Ageing of bone
After the achievement of PBM, the skeleton continues to change (Heaney et al. 2000). To optimize
its strength and minimize its weight, the bone architecture is reorganized in a process called bone
mineral apposition (Schoenau et al. 2001). Bone strength depends on both material and geometric
properties (Heaney 2000, van der Meulen 2001); generally, the bigger the bone, the stronger the
bone. To maximize its strength, the bone material is placed as far from its mean axis as possible
(Seeman 2003a), in nature reflected as mineral apposition from the endochondral envelope to the
outer surface of the bone. During growth this mineral apposition increases both the outer diameter
of the bone and the wall thickness (Seeman 2003a, 2004).
Periosteal expansion is facilitated by androgens. In addition, growth hormone, IGF-1 and
mechanical loading are thought to be the primary modulators of periosteal apposition. On the other
hand, oestrogens are responsible for the opposite mineral apposition called endocortical apposition
(subtraction) (Schoenau et al. 2001). In endocortical subtraction, the mineral is placed on the
endochondral envelope, which maintains the outer diameter but decreases the inner diameter of the
bone. Here, the mineral plays no real role in the mechanical strength of the bone, but it serves as a
mineral reservoir that could easily be mobilized to meet the needs of the body in for example,
pregnancy or lactation (Schiessl et al. 1998, Schoenau et al. 2001).
During ageing, the mineral apposition varies from the inner cortex to the outer cortex, increasing
the outer diameter of bone and thus maintaining the width of the bony wall (Seeman 2003, 2004).
The main goal is to make the bones as strong as possible using as little material as possible
(Schoenau et al. 2001). Figure 4 is a schematic of longitudinal growth and bone mass
reorganization.
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Figure 4. During growth cross-sectional area and bone length increase (A). The shape of bone
might also alter. Periosteal apposition increases whole bone diameter and wall thickness (B).
Endochondral subtraction; whole bone diameter is maintained, but wall thickness is increased (C).
Skeletal integrity and bone mass are relativly stable between the ages of 20 and 40 years. However,
lifestyle factors, such as nutrition, smoking, alcohol abuse, physical activity and disease
(malabsorption, anorexia, hypogynadism, etc.), and certain medicines contribute to changes in
BMD, which varies 1-2% annually (Bergstralh et al. 1990). Bone loss is a normal physiological
process; it occurs in all humans due to hormonal changes and declines in physical activity and
muscle mass. After menopause, bone loss accelerates in women, as the anabolic effect of oestrogens
ceases. By the age of 80 years women are estimated to lose 30-50% of their bone mass (Väänänen
1996) and men from 25-30% (Fig. 5).
Lower PBM and earlier and greater bone loss are the main reasons why women are more likely to
suffer from osteoporosis than men. Of population aged over 50 years, an estimated 20% of women
and 14% of men will suffer from osteoporotic fracture during their life time. The incidence of
osteoporosis was speculated to increase three fold by 2030, based on the incidence of hip fracture
from 1960 to 1994 (Kannus et al. 1999). At this point, this seems unlikely since only 8000 hip
A
B
C
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fractures occurred in 2006, which is 2000 less than predicted by Kannus et al. (1999). However, a
newer publication by Kannus et al. (2006) showed a decreasing trend since 1994 for hip fractures in
women but a slight increase in men. Hip fractures have been considered the final outcome variable
for osteoporosis, but whether hip fractures actually reflect the general well-being of the elderly or
the standards of care (Jensen et al. 2002) rather than osteoporosis itself is arguable. Typically, hip
fractures occur in elderly persons after a fall. There are a variety of risk factors for falls, including
number of used medicines, environmental factors, personal motor functioning and vision. Low-
energy fractures of the vertebra or lower arm are proposed to predict the incidence of osteoporosis
more clearly than the current strategy (Johnell & Kanis 2006).
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Figure 5. Lifetime bone mass accrual and loss among men and women. Error bars represent SD.
data from http://courses.washington.edu/bonephys/index.html
2.2.3 Bone modelling and remodelling
Bone is living material that constantly renews in a process called remodelling; osteoclasts remove
old bone by resorption and osteoblasts form new bone (Parfitt 1988) (Fig. 6). In addition, the basic
multicellular unit in which the bone remodelling occurs contains lining cells and osteocytes that
also participate in the process in ways as yet uncharacterized. During growth there is less
27
remodelling but more modelling, which means that new osteons are formed and more bone is
formed than resorbed i.e. the balance is placed more on the osteoblastic site (Parfitt 1988).
Modelling occurs predominantly at the epiphyses of long bones, altering the shape and size of bone
(Rauch et al. 2001a).
In healthy adults, a balance exists between osteoclasts and osteoblasts to maintain skeletal function
and integrity. A negative calcium balance initiates the remodelling cycle at the edge of the bone.
Both lowered and accelerated bone turnover is harmful to bone health, as they affect the
homeostasis between osteoclasts and osteoblasts, and bone turnover becomes uncoupled (Eastell et
al. 1993, Parfitt 2003). Bone turnover accelerates and becomes uncoupled after menopause,
reflected as an increase in the number of resorption cavities and undermineralized osteons. In
lowered bone turnover by contrast, microcracks tend to accumulate and bone strength decreases
(Seeman 2004). Microcracks are recognized by osteocytes that initiate the remodelling cycle in the
inner structures of bone (Parfitt 1988). Lowered bone turnover is seen more commonly among men,
in African Americans and after antiresorptive therapy in osteopenic patients (Seeman 2004).
1.
2.
3.
4.
Figure 6. Remodelling cycle in bone starts with the resting phase (1), where lining cells cover the
edge of bone. In the resorption phase (2), multinuclear osteoclasts secrete proteolytic enzymes to
break down the old bone matrix. A resorption cavity is formed. During the formation phase (3),
osteoblasts refill the cavity with collagen. During the maturation phase (4), the collagenous matrix
is mineralized. Based on Parfitt (1988).
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Remodelling rates differ between cortical and trabecular bone. Trabecular bone, located mainly in
the epiphyses of long bones and the vertebra, is metabolically more active. It contains more cells
and nutrients are more abundant than in the cortex; its remodelling cycle is thefore shorter than in
the cortex. The remodelling cycle in trabecular bone takes about three months, with resorption
lasting for two weeks, whereas the cycle in cortical bone is four months (Dempster 1995). All bones
are covered with a variable layer of cortical bone, but most cortical bone is situated in the diaphysis
of long bones. Only 3% of cortical bone is renewed annually, while the proportion is 25% in
trabecular bone (Dempster 1995). A number of hormones, including PTH, sex hormones, growth
hormone, thyroid hormones and glucocorticoids, affect bone turnover. In addition, such local
factors as growth factors, cytokines and prostaglandins contribute to local changes.
2.2.3.1 Markers of bone remodelling
Bone remodelling markers are specific biomarkers of bone turnover that are utilized in preclinical
and clinical trials (Watts 1999). The biomarkers of bone are divided into subgroups describing
either bone formation or resorption. Although some markers are specifically linked to certain phase
of the remodelling cycle, (for example TRACP), others describe the general turnover rate (for
example BALP) (Seibel 2003).
Bone formation markers are biproducts formed during the production of new bone. The main
function of osteoblasts is to produce collagen type I matrix. Procollagen peptides or their fractions,
like carboxy-terminal propeptide of type I procollagen (PICP) or amino-terminal propeptide of type
I procollagen (PINP) are formed during collagen matrix synthesis (Fig. 6). These can be detected in
serum or urine with highly specific methods that reflect bone formation rate (Tähtelä et al. 1997).
Another well-known formation marker is bone-specific alkaline phosphatase (BALP), which
describes osteoblastic function. BALP is located in the plasma membrane of osteoblasts and the
measured activity reflects the function of the osteoblasts. Another marker, osteocalcin (OC), is non-
collagenous protein that mature osteoblasts secrete when bone matrix has been mineralized. The
amount of OC can be detected in the serum and is highly bone-specific. New methods are currently
being invented to detect different fragments of OC to further elucidate the turnover process (Ivaska
et al. 2004).
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Bone-resorbing cells, osteoclasts, secrete proteolytic enzymes, cathepsins, which in a normal
situation start the degradation of the bone matrix, but other enzymes, such as metalloproteinase,
accompany them. However, alternative collagen cleavage sites predominate in a pathological
resorption process (e.g. Nishi et al. 1999), and possibly also in different sites of bones (Everts et al.
2006). Deoxypyridinoline (DPyr), pyridinolines (Pyr) or peptides from the amino- or
carboxyterminal telopeptides are released when bone-specific type I collagen is broken down.
These pyridinoline compounds and crosslinks are released into the circulation, and as they are not
recycled in the body, they could serve as biomarkers. The latest marker on the market is serum
tartrate-resistant acid phosphatase (TRACP), which describes either osteoclastic activity or number
according to different isoforms (Halleen et al. 2006).
There are a number of reasons why resorption markers are more frequently used than formation
markers in prospective studies. Resorption is thought to be more easily affected than formation, but
in fact the bone remodelling cycle starts with the resorption of old bone, and in many bone diseases,
accelerated bone resorption is the underlying reason (Borderie et al. 2001). In general, within three
months, an effect of the therapy is noticed in remodelling markers, but still when interpreting the
results individual, diurnal and seasonal variation should be taken into consideration as well as the
menstrual cycle in females (Dempster 1995). In addition, remodelling markers are utilized in the
follow-up of bone disease or metastasis. While remodelling markers are not related to the diagnosis
of osteoporosis, they could be utilized to predict fractures.
Some researchers (Van Coeverden et al. 2002, Fares et al. 2003) have observed that bone
remodelling markers tend to vary during puberty. The concentration of bone remodelling markers
increases gradually as puberty proceeds, peaking at mid puberty. After menarche, bone remodelling
markers decrease again, and they reach adult levels around 16-20 years, a bit earlier in girls than
boys (Van Coeverden et al. 2002, Fares et al. 2003). This growth-related variation is seen in both
remodelling markers, but to greater extent in formation markers.
2.2.4 Assessments of bone mass and structure
The current primary diagnostic technique for BMD is dual-energy x-ray absorptiometry (DXA) but
other x-ray and ultrasound techniques have been widely used for the same purpose. Although
ultrasound was abandoned in calcaneus BMD measurements, it has been reintroduced to
characterize human trabecular bone microstructure (Hakulinen et al. 2006). Mineral properties are
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commonly accepted as being responsible for bone strength, but increasingly more emphasis is being
placed on the microarchitecture of bone (Parfitt 1988). Bone microarchitecture alters in
osteoporosis (Chappard et al. 2005). In addition, microarchitecture may explain gender differences
(Seeman 2004) and is related to fracture risk assessment (Legrand et al. 2007). Parameters derived
by microcomputed tomography, microCT, describe the histomorphometry of bone, especially
trabecular bone. For preclinical use, the microCT application is suitable for ex vivo and in vivo
samples. Human applications require bone biopsy from transiliac bone, which is unethical in studies
involving healthy human beings. In future, images of CT will provide us with further understanding
of the structure and properties of bone during growth.
2.2.4.1 Dual-energy x-ray absorptiometry (DXA)
DXA is a non-invasive method to quantify bone mass. The method for measuring bone is calibrated
against a hydroxyapatite phantom. The radiation dose is highly localized, and the effective dose is
around 2.1 microSiever (µSv) which is equal to a 1-to 2-days radiation dose from the environment.
DXA gives a planar image of bone, allowing the bone mineral content of the whole body or from
specific sites, such as lumbar spine, femoral neck (Fig. 7) or forearm, to be calculated. It is crucial
to understand that the size and shape of the bone affects the bone mineral content (BMC) (Heaney
2003). A typically parameter used, the bone mineral density (BMD), which is calculated by
dividing the BMC with corresponding bone area (BA) (mg/mm2), predicts apparent rather than real
density. DXA-derived BMD is used in the diagnosis of osteoporosis (Compston et al. 1995, Table
4), and it is thought to predict fractures most reliably, especially in the femoral neck (Nevitt et al.
1994). A change of one standard deviation in the BMD increases fracture risk 1.5-3.0 times
(Compston et al. 1995). The use of BMD in growth studies is questionable, as it is size-related
(Heaney 2003). However, no consensus exists about BMC, BMD or BA to describe the size of the
bone among growing children, but are recommended to use all three to characterize the situation
most clearly.
The precision of DXA is fairly good, around 1%. Errors are related to the movement of the body
and placement of subjects during measurement. Reference values are used to categorize subjects’
results. The summary of T and Z scores is presented in Table 5. Although areal BMD reflects bone
fracture risk quite well, it revels virtually nothing about bones’ inner structure, geometry or mass
distribution, which are important determinants of bone strength in general (Seeman 2004).
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Figure 7. DXA scans of the lumbar spine (L1-L4) and left hip.
Table 4. Standardized reference values in evaluating areal BMD results (Compston et al. 1995).
Value T-score Z-score
Description a young adult of the same gender
with peak bone mass
other people in same age group and of same
size and gender e.g. children
> -1 Normal BMD Normal BMD
-1- (-2.5) Osteopenia
<-2.5 Osteoporosis
2.2.4.2 Peripheral quantitative computed tomography (pQCT)
Peripheral quantitative computed tomography (pQCT) elucidates bone structure and geometry (Fig.
8 and 9). With the pQCT scanner, the radiation source rotates around the measured particle and
creates an image of the cross-section of the bone. Typically measured sites are the radius and tibia
from different positions. Because of its cross-sectional nature, pQCT gives the bone composition or
cortical to trabecular bone ratio. In addition, the actual bone volumetric density (vBMD) is
calculated. The effective dose is higher than in DXA, 0.22 µSv (Meditechnish, Stratec), but this is
more localized than in DXA. Fig. 6 presents simple parameters that could be obtained from pQCT
measurements. In addition, there are a number of parameters that can be calculated to estimate
mechanical strength of long bone or its resistance to torsion or bending stress (Schoenau et al.
2001). One of basic ones is section modulus, which indicates resistance of diaphyseal bone to stress.
Another much used parameter is polar moment of inertia, which is inversely related to shear stress
(Specker & Schoenau 2005). Reference values are currently available for adult vBMD only.
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Figure 8. Trabecular or cancellous bone is marked with spotted texture. R represents radii and inner
R endocortical or trabecular R. Cortical bone is the cortex surrounding the trabecular bone. Outer R
is also called the total or periosteal radius. Circular ring model is assumed when calculating these
parameters.
Figure 9. An image of distal radius at 4% position with pQCT.
Outer R
Inner R
Cortical Th
Trabecular
Bone Area
Cortical
Bone Area
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2.2.5 Modulators of bone mass
Although 60-80% of PBM is determined by genetic factors (Slemenda et al. 1991), environmental
factors, such as physical activity and nutrition, can also modulate bone mass accretion during
growth (Welten et al. 1994, Bonjour et al. 1997) and maintain it during adulthood. In addition,
nutrients and genes interact with each other (e.g. Ferrari et al. 1998). Low bone mass is a risk factor
for the development of osteoporosis. In primary prevention, the goal is to optimize bone acquisition
during growth, which is justified as tracking of bone mass occurs (Cooper et al. 2001, Matkovic et
al. 2004).
Weight-bearing exercise is crucial for bone mass accrual, which is supported by the mechanostat
theory (Frost et al. 1998, Heaney et al. 2000). Physical activity started in early childhood has been
speculated to be a one-time opportunity to gain long-lasting positive effects on bone (Heaney et al.
2000) since activity in childhood is associated with adult BMD (Slemenda et al. 1991, Pesonen et
al. 2005). The effect of long-term physical activity on bone health becomes apparent with age
(Uusi-Rasi et al. 2002), especially at weight bearing sites. Adults with high-impact, weight-bearing
activities have enlarged bone cortices and thus better bone strength than counterparts without this
type of activity (Kontulainen et al. 2006). Recreational exercise has been shown to have a positive
effect on bone health, possibly induced via muscular performance (Uusi-Rasi et al. 2006). Because
the skeleton adapts to exercise, varying types of activity are recommended to maintain bone mass
and integrity during adulthood (Vainionpää et al. 2007)
There are a number of nutrients that play a role in bone health (e.g. Heaney et al. 2000), one of them
being calcium. Calcium is typically considered the limiting factor for bone mineral accrual (Bailey
et al. 2000). Calcium intake of 1300 mg is required to fulfil the retention rates that are observed in
puberty (Bailey et al. 2000). Positive effects of calcium on bone mineral accrual have been noticed
among children (Specker & Binkley 2003) and adolescent (Bonjour et al. 1997, Rozen et al. 2003).
Calcium supplementation is claimed to extend the growth period or add some extra mineral to
bones (Rozen et al. 2003, Bonjour 2005). How long these positive effects are maintained is another
issue. In adults, the positive effects are not maintained after cessation of supplementation, if the
habitual intake of calcium becomes clearly lower than during the intervention (Prentice 2004).
However, the changes that occur before or during early puberty are thought to be maintained after
supplement cessation (Bonjour et al. 2001, Bonjour 2005), although not all studies agree (e.g. Zhu
et al. 2006).
34
The body apparently can adapt to different levels of calcium intake: thus the absorption from the gut
and the retention to bone vary (Bailey et al. 2000). This adaptation illustrates efficient function of
the vitamin D-PTH –axis in maintaining stable serum calcium concentration (Fig.10). The
adaptation predominates until menopause, but thereafter calcium balance of the body tends to
become negative more easily than before (Heaney et al. 2003b). Diurnal rhythm of PTH It is
suggested to support the maintenance of trabecular bone, while chronically elevated PTH levels are
related to enhanced bone loss (Gabet et al. 2006). Age-related changes in calcium metabolism may
stimulate chronic PTH secretion (North American Menopause Society 2006), but renal function
may also play a role (Vieth et al. 2003).
Figure 10. The regulation of calcium metabolism. Low S-Ca stimulates PTH secretion, which
affects bone and the kidney. In kidney, PTH increases the reabsorption of calcium from urine and
activates 1-alpha-hydroxylase to form calcitriol. Both PTH and calcitriol mobilize calcium from
bone. In addition, calcitriol increases calcium absorption from intestine. Calcitriol regulates its own
concentration by negative feedback.
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2.3 Vitamin D and bone
2.3.1 Association between 25-OHD and bone health
Vitamin D is considered a threshold nutrient for bone health (Heaney et al. 2005), which means that
at a lower concentration than the threshold for serum 25-OH the association with BMD is linear, but
beyond the threshold there are no further benefits (Fig. 10). Recently, an expert board suggested the
vitamin D threshold for optimal bone health (Dawson-Hughes et al. 2005) should be over 80 nmol/l.
This conclusion is based on different studies worldwide in which a concentration of 80 nmol/l is
shown to benefit calcium absorption (Heaney et al. 2003b), prevent bone loss among the elderly
(Dawson-Hughes et al. 1995), decrease fracture risk among the elderly (Dawson-Hughes et al.
1997), be associated with higher BMD for both genders and different races (Bischoff-Ferrari et al.
2004a) and suppress PTH secretion (Vieth et al. 2003). In addition, for subjects over 70 years, an
additional benefit for bone health is achieved if a vitamin D status above 100 nmol/l is maintained
(Vieth et al. 2003). This is based on findings that elderly subjects require higher doses of vitamin D
to suppress PTH secretion, possibly because of lowered kidney function.
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Figure 11. Association between BMD and serum 25-OHD concentration (based on Heaney et al.
2005).
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2.3.2 Effect of seasonal variation on bone remodelling
During winter there is limited amount of UVB irradiation to synthesis vitamin D on the skin.
Together with an inadequate vitamin D supply from the diet, this leads to deprivation of vitamin D
stores. To maintain adequate serum calcium concentration, PTH secretion increases and further
activates vitamin D metabolism. This seasonal variation increases bone resorption and decreases
formation during the winter and possibly has opposite effect during the summer (e.g. Rosen et al.
1994). A positive association between vitamin D status and formative markers has been described
(Woitge et al. 1998), and in follow-up studies resorptive markers increase during winter (Storm et
al. 1998, Woitge et al. 2000, Rapuri et al. 2002) due to increased PTH secretion.
Seasonal variation in serum 25-OHD, PTH and possibly 1,25(OH)2D is believed to determine the
seasonal variation in bone mass (Krall et al. 1989, Dawson-Hughes & Harris 1993). In healthy
adults, the seasonal variation in bone mass is around 1-2% (Bergstralh et al. 1990, Meier et al.
2004), whereas in the elderly it comprises a 6-8% change, at least, according to cross-sectional
studies (Rapuri et al. 2002, Bhattoa et al. 2004). Furthermore, a prospective community-based study
demonstrated that the rates of bone fractures and falls follow this seasonal periodicity (Jacobsen et
al. 1991, Pasco et al. 2004). These observations were made in Australia and the United States,
taking into account the geographical levels as well as the influence of winter weather conditions.
The peak in fracture incidence during the colder season is most obvious in warm locations without
icy and slippery weather conditions (Bischoff-Ferrari & Dawson-Hughes 2007).
2.3.3 Effect of vitamin D on bone metabolism in children and adolescents
Vitamin D deficiency in childhood causes rickets, which is characterized by disturbed bone
formation. Clinical symptoms include swollen growth plates in long bones and deformed legs and
pelvis; in severe cases the spine is affected as well. In rickets, mineralization of growth plate
cartilage is stunted and bone formation rate is accelerated; new osteoids are formed, but they do not
mature because of undermineralization (Parfitt 2003). Poor mineralization of bone deteriorates bone
strength, which is seen as bending of long bones. Especially weight-bearing bones are affected
(Bishop 1999). When diagnosed early, rickets can be cured with extensive vitamin D therapy, but if
deformities are severe and growth plates start to mature in puberty, no cure exists (DeLuca 1979).
Studies have shown that vitamin D therapy stabilizes bone turnover in rickets (Scariano et al. 1995).
Osteomalacia was the main cause of death among childbearing women in 19th century England
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(Wharton & Bishop 2003). Underdeveloped or malformed pelvis hindered the delivery and caused
the death of the mother or both mother and baby (Ala-Houhala 2002).
In the early 1900s, the incidence of rickets was 44-80% in Finland (Ylppö 1925, Leppo 1940).
Supplementing the diets of newborns and small children with vitamin D started in the 1940s in
Finland. Initially the doses were 2400-4000 IU (60-100 µg) for weaning and small children and
4000-6000 IU (100-150 µg) for older children. However, these doses were soon deemed too
extensive, as they caused hypercalcaemia and kidney stones (Hallman et al. 1964). In 1960, the
recommendation was diminished to 2000 IU (50 µg), and a decade later to 1000 IU (25 µg). Since
1970, the incidence of rickets has been less that 0.6% according to child welfare clinics (Ala-
Houhala et al. 1995). In 1992, the guidelines for weaning and small children declined to 400 IU (10
µg); in daily use, this was considered safe and adequate intake for children aged under 3 years (Ala-
Houhala et al. 1995). Cases of rickets are very rare today in Finland, but those present are virtually
always related to insufficient of vitamin D supplementation.
Some vitamin D supplementation studies have been carried out in healthy children and adolescents
(Docio et al. 1998, Guillemant et al. 2001, Lehtonen-Veromaa et al. 2002, Moyer-Mileur et al.
2003, Cheng et al. 2006, El-Hajj Fuleihan et al. 2006), but only four of these (Lehtonen-Veromaa et
al. 2002, Moyer-Mileur et al. 2003, Cheng et al. 2006, El-Hajj Fuleihan et al. 2006) had BMD as
the outcome variable. In studies of Guillemant et al. (2001) and El-Hajj Fuleihan et al. (2006),
dosages were notably higher than considered safe for continuous longitudinal use by children under
11 years of age (Scientific Committee on Food, 2002). Moreover, Guillemant et al. (2001) reported
that three oral doses of 2.5 mg of vitamin D3 at 2-month intervals for 13-to 17–year-old boys
maintained the post-summer 25-OHD concentration at 55 nmol/l throughout the winter. In the study
of El-Hajj Fuleihan et al. (2006), adolescent girls reached a S-25-OHD of 95 nmol/l (measured with
competitive protein binding assay) with a daily dose of 50 µg.
A prospective study from Switzerland showed that children given vitamin D supplementation for 1-
2 years during early childhood had higher BMD 13 years later than control subjects who had
received no supplementation (Zamora et al. 1999). Lehtonen-Veromaa et al. (2002) reported that
supplementation benefited more girls with low initial vitamin D status than those that initially had
adequate vitamin D status; BMAD increased more in subgroup with low vitamin D status than in
subgroup with adequate vitamin D status, although their results concerning 25-OHD were
suspicious because either S-25-OHD or the assessment method did not respond to D2
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supplementation. Adolescent girls from Libanon responded to vitamin D supplementation by
increasing total hip BMC as compared with placebo (El-Hajj Fuleihan et al. 2006), but Cheng et al.
(2005) did not report any beneficial effects in their vitamin D intervention study with 10-to 11-year-
old Finnish girls. However, they did find a positive association between higher 25-OHD together
with low PTH and higher BMD in a cross-sectional study (Cheng et al. 2003), which is in line with
the observation of Outila et al. (2001). In addition, combination therapy of calcium and vitamin D
improved trabecular bone BMD in 12-year-old girls compared with the unsupplemented placebo-
receiving group in a one-year study (Moyer-Mileur et al. 2003).
2.3.4 Effect of vitamin D on bone metabolism in adults and the elderly
Vitamin D deficiency induces osteomalacia in adults, in which the body’s calcium balance becomes
negative and calcium is mobilized from bone. Bone formation rate is lowered, which contributes to
increased osteoid thickness and osteoid volume per unit of bone volume, as observed in histological
experiments (Parfitt 2003). In DXA, this is seen as decreased BMD, but osteomalacia could not be
distinguished from osteoporosis. From the bone biopsy of the ilium, trabecular structure of the bone
is maintained in osteomalacia, but under the cortex an undermineralized area is present (Parfitt
2003). Muscle weakness and pain, also called myopathy, are typically associated with osteomalacia.
Osteoporosis, in turn is characterized by lowered BMD due to accelerated bone turnover, in which
more bone is resorbed than formed. The inner structure of bone is affected, which is noted as a
decrease in bony bridges in bone biopsy.
There is general agreement that insufficient vitamin D status promotes the development of
osteoporosis (e.g. Zitterman 2003). Vitamin D intervention studies have been done mainly in the
elderly to prevent bone loss (Dawson-Hughes et al. 1995, Ooms et al. 1995, Chapuy et al. 2002,
Trivedi et al. 2003). Intervention trials in which vitamin D supplementation was beneficial to BMD
or decreased fracture risk are few (Dawson-Hughes et al. 1995, Chapuy et al. 2002), while others
have detected no change (Hunter et al. 2000, Patel et al. 2001, Grant et al. 2005). The effective dose
of vitamin D varies between subjects with weight and initial vitamin D status having an impact on
response (Heaney et al. 2003a). In many studies where positive effects were seen, calcium
supplementation was included as well (Chapuy et al. 1992, Dawson-Hughes et al. 1997); thus, the
calcium intake is thought to modulate the vitamin D requirement (Lips 2004). A recent meta-
analysis of vitamin D (Bischoff-Ferrari & Dawson-Hughes 2007) supports the beneficial effect of
vitamin D on bone health maintenance, but also states that the dose required to reach a serum 25-
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OHD of at least 75 nmol/l is 17.5-20 µg (700-800 IU), which is in line with the report of Vieth et al.
(2007).
2.3.5 Mechanisms of action of vitamin D on bone
The main effect of vitamin D on bone is proposed to be mediated through calcium balance, as
vitamin D-deficient persons with adequate calcium intake benefit from vitamin D supplementation
(Lips 2004, Heaney 2005). When positive effects on bone health have been seen, the calcium
balance was improved (Heaney. 2005). Vitamin D intake increases calcium absorption from the
intestine and promotes mineralization of the skeleton. Recently, an alternative mechanism by which
vitamin D might affect bone via muscles or a Gc-globulin-related mechanism has been described
(Lauridsen et al. 2004). These routes do not exclude each other. Although the systemic effect of
calcitriol focuses on the body calcium balance, the other mechanisms make sense in this context as
well.
In osteoblast cells, as in many other cells, 1-?-hydroxylases are present, which enables the cells to
form calcitriol locally. Calcitriol upregulates matrix protein synthesis in osteoblasts (Xue et al.
2006), thus reinforcing bone formation independently of PTH. In addition, vitamin D has a role in
muscle performance and muscle strength maintenance via specific nuclear receptor (e.g. Bischoff-
Ferrari et al. 2004b, Wicherts et al. 2007),which is observed especially among the elderly, but
possibly is also present among children. However, in both rickets and osteomalacia, clinical
symptoms include myopathy (Parfitt 2003). Because muscles surround bones and induce
mechanostatic loading to bone (Heaney et al. 2000), this could be considered a mechanism affecting
bone as well. Finally, 25-OHD may have an independent and direct effect on bone since Gc-
globulin transporting 25-OHD in the circulation forms a complex with transmembrane proteins of
osteoclasts. The genotype with the lowest Gc concentration had less fractures that other genotypes
in a study of 600 pre-menopausal women (Lauridsen et al. 2005). However, the association between
Gc genotype and bone health requires further investigations.
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3. AIMS OF THE STUDY
The objectives of this thesis were to characterize the effects of vitamin D supplementation on
different outcome variables such as S-25-OHD, S-iPTH and BMD. A deeper goal was to elucidate
adequate vitamin D intake to preserve bone health for each target group (adolescent girls, men and
the elderly).
Specific research questions as follows:
Study I: Does vitamin D increase bone mineral accretion dose-dependently among adolescent girls
with high habitual intake of calcium in a randomized, placebo-controlled one-year intervention?
Study II: Do S-25-OHD, S-iPTH, BMD or bone remodelling markers vary between different
months in early and mid-pubertal Caucasian girls in a cross-sectional setting?
Study III: Does vitamin D increase S-25-OHD concentration dose-dependently in ambulatory
elderly women? Which dose increases vitamin D status above the insufficient level (S-25-OHD?50
nmol/l) and decreases S-iPTH concentration within 12 weeks?
Study IV: Is there seasonal variation in bone remodelling markers and radius BMD in a 6-month
study? Which vitamin D dose prevents these changes among healthy 21-to 49-year-old men?
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4. SUBJECTS AND METHODS
4.1 Subject recruitment and study designs
4.1.1 Intervention trial in adolescent girls (I)
A total of 228 adolescent girls, aged 11-12 years were studied in the capital region of Helsinki
(60oN), in southern Finland. Recruitment was conducted in primary schools. The subjects were
healthy, used no medicines known to affect calcium metabolism and were of Caucasian origin.
The subjects first presented between September 2001 and March 2002 and were later examined
every 6th month. The study lasted one year. During each visit height, weight and pubertal
development were measured. Background data on diet, physical activity and serum and second void
urinary samples were collected. Bone mineral density (BMD) was measured twice with a Hologic
DXA (Fig. 11).
A stratified randomization process was performed three times. The stratification factor was pubertal
development, Tanner stage. At each Tanner stage, an equal number of subjects was randomly
assigned to three treatment groups receiving 0 ?g (placebo), 5 ?g, or 10 ?g of vitamin D3 as  a
supplement (Scanpharm Ltd., Denmark). The vitamin D3 content of the tablets was confirmed by an
analysis performed at the Danish Institute for Food and Veterinary Research, Söborg, Denmark.
The subjects were instructed to take one tablet daily for 28 days during each month of the one-year
study. The blister packs were returned to researchers during each visit, and compliance was
confirmed by pill counts. The study was double-blinded.
4.1.2 Cross-sectional study of adolescent girls (II)
Girls entering the longitudinal intervention study and scoring Tanner stage 2 (=early puberty) or 3
(=mid-puberty) were selected for the cross-sectional study (N=196). Data were collected during the
first visit and included fasting blood samples, second void urinary samples, DXA-measured BMD
and background information.
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Figure 12. Flow chart of Study I.
4.1.3 Short-term intervention in elderly women (III)
Women aged 65-85 years were recruited from the Helsinki area by an announcement in a local
paper in Helsinki. Fifty-two women participated in the 12-week intervention trial from the
beginning of January to April 2002, when UVB radiation is scarce in Finland (Fig. 12). Of the 52
enrolled subjects, three dropped out due to the strict schedule of the study; thus, 49 completed the
study. According to the protocol, travelling to sunny places was not allowed during the study.
Subjects were randomly assigned to four groups receiving placebo, 5 ?g, 10 ?g or 20 ?g of vitamin
D3 a day. Scanpharm Ltd. (Birkerød, Denmark) supplied the vitamin D3 tablet for groups receiving
placebo, 5 ?g or 10 ?g of supplementation per day. Ferrosan Ltd. (Espoo, Finland) supplied the
vitamin D3 drops used in the 20-?g group.
First visit: Blood and urine samples, DXA
N = 76
 placebo
Second visit: Blood and urine samples
Data collected
on puberty
development,
nutrient intakes
and physical
activity
Third visit: Blood and urine samples, DXA
Recruitment of 228 11-to 12-years-old girls from
primary schools during Sept 01-March 02Time
6 mo
12 mo
2 lost
interest
8 lost
interest,
1 moved
away
1 lost
interest,
1 moved
away
  N = 76
   5 µg
N = 76
   10 µg
1 lost
interest
1 lost
interest,
1 moved
away
Completed intervention with ? 80% compliance
N = 73
placebo
N = 65
   5 µg
   N = 74
   10 µg
N = 64
placebo
N = 58
5 µg
N = 71
10 µg
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Recruitment of 65-to 85-year-old women via a local
paper in December 2001
Ø Exclusion criteria: liver or kidney disease
Randomized into four groups, N=52
Ø Background data and FFQ
Placebo
N = 13
10 µg
N = 13
20 µg
N = 13
Study lasted 12 weeks from January to early April 2002
Ø sampling every other week (7 times)
Ø 24-our urine collected 3 times
Ø FFQ was filled out again
5 µg
N = 13
Figure 13. Design of Study III.
4.1.4 Intervention trial in healthy adult men (IV)
Men of Caucasian origin, aged 21-49 years, were recruited from the Helsinki area by an
announcement in a campus area of the University of Helsinki. This was a randomized, double-blind,
placebo-controlled, 6-month vitamin D intervention study in which 54 men participated (Fig. 13).
Participants were allocated to three groups and assigned four tablets consisting of 20 µg (800 IU),
10 µg (400 IU), or placebo with morning meals daily. All tablets were provided by Verman Oy,
Minisun, and were similar in size and taste. Subjects were asked to take tablets until trial closure
and to return any unused tablets during the study to researchers for pill counting. In addition,
participants were advised to record the days they forgot to take pills in a follow-up diary.
Compliance was confirmed with pill counts and the diary. A total of 49 men completed the study.
According to the protocol, travelling to sunny places or using tanning salons was not allowed
during the study.
Randomization was performed by minimizing the variation of age, weight, initial S-25-OHD status
and dietary intake of vitamin D in three groups.
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The trial lasted from the beginning of November until the end of April, altogether 26 weeks. Fasting
blood samplings were collected at 5-to 6-week intervals, altogether 6 times at the same time-points
during the day between 7:30 and 9:30 am. Body weight, height and distal and proximal radius BMD
were measured by peripheral QCT at enrolment and after 6 months.
Figure 14. Flow chart of Study IV.
4.1.5 Ethical consideration
For each study protocol, ethical approval was obtained from the Ethics Committee of the Helsinki
and Uusimaa Hospital District. In addition, the protocol of Study I was disclosed to the National
Institute of Medicine. The subjects and parents of minors gave informed written consent in accord
with the Helsinki Declaration before entering the study. Subjects could withdraw their participation
without a reason at any time. Subjects were provided copies of their personal results for dietary
intakes of calcium and vitamin D, S-25-OHD concentration and BMD. The overseeing doctor
discussed low BMD values or other unhealthy findings with subjects.
Recruitment of 54 healthy 21-to 49-year-old men from a
campus area in September-October 2004
Screening blood sample, background data by
questionnaire and radius BMD by pQCT
(randomization by S-25-OHD, age, weight and vitamin D
intake)
Placebo
N = 18
10 µg
N = 18
20 µg
N = 18
2 lost
interest
2 lost
interest
2 lost
interest
Study visits were at 5-to 6-week intervals
- sampling altogether 6 times
- dietary intake of vitamin was rechecked in February
- radius BMD by pQCT at 6 months
Time:
November
6 months:
April
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4.2 Methods
4.2.1 Background characteristics (I-IV)
All subjects completed a form containing questions on their medical history, use of vitamin D and
calcium supplements, time spent outdoors, sunny holidays and physical activity. Weight and height
of subjects were measured at enrolment and at the end of the study.
The physical activity of subjects consisted of school or work trips, guided leisure time activity and
leisure time activity on their own (Outila et al. 2001). The activity was calculated in minutes per
day.
In Studies I and II, the pubertal stage of the subject was assessed ad modum Tanner (Marshall &
Tanner 1969). A self-assessment protocol concerning the evaluation of breast development and
timing of menarche was completed during an interview.
Dietary intakes of vitamin D and calcium were assessed with a food frequency questionnaire (FFQ),
a validated semi-quantitative questionnaire covering over 70 foods (Outila et al. 2001). The nutrient
contents of the foods were calculated using the Finnish National Food Composition Database,
Fineli®, version 2001, which is maintained by Nutrition Unit of the National Public Health Institute
of Finland.
All forms were checked by the researchers, and if needed, additional information was requested.
Table 6 summarizes background and nutritional data of subjects in each study presented with means
(SDs).
Table 6. Background data in Studies I-IV presented with mean (SD) and median.
Study N,
gender
Age,
years
Height,
cm
Weight,
kg
Physical
activity,
min/d
Vitamin D
intake, µg/d
Calcium
intake,
mg/d
Supplement
users, %
I 228, F 11.4
(0.4)
149.2
(7.5)
42.4
(9.8)
169
(92)
5.6 (4.0)
4.5
1260
(550)
17
II 196, F 11.4
(0.4)
149.0
(7.2)
41.7
(9.0)
169
(90)
5.8 (4.3)
4.5
1230
(530)
18.3
III 52, F 71.7
(3.9)
162.1
(6.4)
68.7
(12.1)
- 10.2 (5.7)
9.2
1050
(420)
33.3
IV 54, M 28.7
(6.7)
178.6
(7.8)
79.2
(14.2)
42
(32)
7.7 (5.2)
6.6
1340
(870)
9.2
- not defined
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4.2.2 Laboratory measurements (I-IV)
Overnight fasting blood samples were collected in the morning between 7:30-9:30 to avoid the
diurnal rhythm of PTH to confound the results. Venoject gel tubes were used to obtain clear sera.
Blood samples were processed within 3 h and centrifuged at 3000 rpm for 15 min. Serum was
stored in aliquots at -70°C until analysis.
From serum samples, 25-OHD concentration (S-25-OHD2 and S-25-OHD3) was measured with
HPLC analysis at the Danish Institute for Food and Veterinary Research, Söborg, Denmark (I-III).
In Study IV, S-25-OHD was measured with an OCTEIA® enzyme immunoassay (IDS, Boldon,
UK). The accuracy of both methods was monitored by participation in the Vitamin D External
Quality Assessment Scheme (DEQAS, Charing Cross Hospital, London, UK). Standardized
concentrations of 25-OHD were provided for Study IV. Other parameters measured from serum
samples are summarized in Table 7.
Second void urine samples were collected in Studies I, II and IV. In Study III, 24-hour urine
collections were performed. Portions of urine were stored at -20°C until analysis. Calcium and
phosphate secretion together with bone resorption markers deoxypyridinoline and pyridinoline were
measured from urine samples (Table 7) with specific methods.
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Table 7. Summary of laboratory measurements in Studies I-IV.
Variable Biomarker Method Study Location
of
analysis
CV%
intra- and
interassays
Vitamin D status
Calcidiol S-25-OHD HPLC I-III DFVR 4.3, 6.3
S-25-OHD EIA IV HU 2.0. 7.9
Parathyroid hormone S-iPTH EIA I-IV HU 2.3, 4.0
Calcium metabolism
Serum calcium S-Ca Spectrophotometric I-IV HU <10
Urinary calcium U-Ca Spectrophotometric I-IV
Serum phosphate S-Pi Spectrophotometric I-IV HU <5
Urinary phosphate U-Pi Spectrophotometric I-IV
Bone formation
Osteocalcin S-OC ELISA I, II UCC <11
Bone-specific alkaline
phosphatase activity
S-BALP EIA IV HU 2.9, 5.0
Bone resorption
Deoxypyridinoline U-DPyr HPLC I, II UCC 3
Pyridinoline U-Pyr HPLC I, II UCC 5
Tartrate resistant acid
phosphatase
S-TRACP EIA IV HU 4.0, 4.0
HPLC high performance liquid chromatography
EIA enzyme immunoassay
ELISA enzyme linked immunoassay
DFVR, Danish Institute for Food and Veterinary Research, Søborg, Denmark
HU, Department of Applied Chemistry and Microbiology at the University of Helsinki
UCC, Department of Food and Nutritional Sciences and Biosciences Institute, University College
Cork, Ireland
4.2.3 Measurements of bone mineral density
4.2.3.1 DXA (I, II)
The bone area (BA), bone mineral content (BMC) and areal bone mineral density (aBMD) were
measured at the beginning and end of the study with a dual-energy x-ray absorptiometry (DXA)
model A (QDR 4500, Hologic, Waltham, MA, USA) from the lumbar spine L1-L4 vertebrae and
left femur region. The femur region includes the femoral neck, trochanter, Ward’s triangle and the
inter-area, which is analysed as a single area of interest. Calibration of the measurement was
performed using a spine phantom; the interassay CV for the phantom was 0.31%. Intra-assay CVs
were determined with duplicate measurements of 10 subjects. CVs for BMD in the left femur and
lumbar vertebrae were 0.67% and 1.39%, respectively.
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The site-specific bone mineral augmentation was determined following changes in BMC, as
suggested for growth studies (Heaney 2003). The change in BA confounds the interpretation of
BMC since the correlation between the change in BMC and BA was strong (r =0.8, P<0.001); we
adjusted BMC with BA (Prentice et al. 1994, Carter et al. 2001, Lehtonen-Veromaa et al. 2002,
Mølgaard et al. 2004). In addition, BMC values were adjusted for change in weight and Tanner
stage.
4.2.3.2 pQCT (IV)
Peripheral quantitative computed tomography (pQCT) to acquire peripheral BMD from the non-
dominant radius was used in Study IV. Two 2-mm thick slices (voxel size of 0.50 mm) were
scanned in the proximal direction from the distal radius (XCT-2000, Stratec, Pforzheim, Germany).
Sites were 4% and 66% of the axial length, referred to as the distal and proximal radii in this text. A
30-mm planar scout view was used to locate a standard anatomical site for the radius reference line
at the distal end. Length of the forearm was defined as the distance between the olecranon and the
processus styloideus, forming the basis for the location of distal and proximal slices. At 6 months
measurements were performed at the same sites, which were recognized by comparing the scout
views.
The data were analysed using version 5.4 of the manufacturer’s software package in which the outer
contour of bone was defined with a threshold of 280 mg/cm3 (Rauch et al. 2001b). The trabecular
(Trab) BMD was determined as a mean density of 45% of the total bone (TB) cross-sectional area
(CSA) at 4% site. At 66% site an additional threshold of 770 mg/cm3 was introduced to define
cortical bone (Cort) BMD. This autoanalyse was performed on all measurements.
Short-term precision (CV%) was determined with duplicate measurements of seven subjects. CVs
for the BMD and CSA in TB, Cort and Trab bone were 2.15, 1.99, 0.71, 0.88 and 1.32, 1.99,
respectively. Phantom scans were executed daily, to maintain quality assurance. The long term
CV% for the phantom BMD and CSA were 1.9, 1.1, 2.7, 0.79 and 0.50, 0.78 in the TB, Cort and
Trab bone, respectively.
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4.2.4 Statistical analyses
Statistical analyses were performed with SPSS version 12.0 for Windows (SPSS Inc., Chicago, IL,
USA, 2000). The normal distribution of variables was tested with the Kolmogorov-Smirnov test. If
normality was not present, logarithmic transformations were performed. The relationship between
variables was shown with Pearson or Spearman correlations, depending on the distribution of the
variables.
Repeated measure analysis of variance (ANOVA) was used to detect the effect of supplementation
on S-25-OHD and S-iPTH in Studies I, III and IV. Comparison between groups was performed with
contrasts. The baseline value of the corresponding variable was used as a covariate in each of these
studies. Baseline characteristics and the total change in variable (?variable = final value- baseline
value) were tested with one-way ANOVA. The post-hoc tests were performed with Tukey’s
honestly significant difference (HSD), Dunnett’s test or least significant difference (LSD)
depending on the feature of the tested variable.
BMD, BMC, bone remodelling markers and corresponding ?variable were tested with both
ANOVA and analysis of covariance (ANCOVA) to illustrate the effect of confounding factors.
Comparison of groups in ANCOVA was performed with contrasts, and for each analysis, covariates
are shown in footnotes. Covariates were selected if their correlation with the outcome variable was
highly significant or if it was known to affect the outcome according to the literature. For example,
with regard to BMC, typical covariates are weight, calcium intake and physical activity (Carter et
al. 2001, Lehtonen-Veromaa et al. 2002).
Evidence from randomized controlled trial (RCT) is novel and allows causality to be determined
(Uhari & Nieminen 2001). Regression models in longitudinal studies can be constructed to define
and clarify causality as well. In Study I, analyses were performed with both an intention-to-threat
(IT) and a compliance-based (CB) method.
Results were considered statistically significant when p < 0.05. P values between 0.05 and 0.1 were
considered trends. In tables, the standard deviation (SD) is presented in parenthesis after the mean
value. In figures, the standard error of the mean (SEM) is shown.
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5. RESULTS
5.1 Dietary intakes of vitamin D and calcium and their corresponding serum 25-OHD and
PTH concentrations (I, III, IV)
Three studies (I-III) were performed before the vitamin D fortification of liquid milk products
began in March 2003 (Fig. 15). In 2004, the Nordic Council of Ministers established new nutrient
recommendations, which are applied in this thesis when evaluating adequacy of dietary intake of
vitamin D.
Figure 15. Timing of studies, fortification and renewed recommendations.
Baseline total intakes of vitamin D and calcium included intake from supplements together with
corresponding 25-OHD and PTH concentrations are presented in Table 8.
Table 8. Baseline values for the intakes of vitamin D and calcium, 25-OHD and PTH presented
with mean (SD).
Study N,
gender
Age, years Total vitamin
D intake,µg/d,
median
Calcium intake,
mg/d
S-25-OHD,
nmol/l
S-iPTH,
pmol/l
I 228, F 11.4 (0.4) 5.6 (4.0) 4.5a 1260 (550) b 47.6 (17.2)c 3.35 (1.07)
III 52, F 71.7 (3.9) 10.2 (5.7) 9.2 1050 (420) 47.2 (14.7)d 3.91 (1.18)
IV 54, M 28.7 (6.7) 7.7 (5.2) 6.6 1340 (870) 67.2 (16.9)e 2.56 (0.74)
a N=223 d January 2002
b N=223  e October 2004
c September 2001 to March 2002
2001 2002 2003 2004 2005
Vitamin D fortification
of milk begun
Study I & II
Study III
Study IV
Nordic nutrition
recommendation for vitamin D
increased
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The use of supplements was expedient (Fig. 16), as with supplements the mean total vitamin D
intake among girls was about 1.2 µg higher than the mean dietary intake of vitamin D. However,
using the median value instead of the mean is advisable because the distribution of the intakes was
not Gaussian. In this case, the difference between total and dietary intake narrowed to 0.5 µg among
girls (Fig. 16), concluding that both intakes were lower than recommended (= 7.5 µg).
Similarly 50% of those studied in each age group had an intake below the recommended level. Note
that Study IV was performed in 2004, when fortification of fluid milk products was ongoing.
Figure 16. Distribution of vitamin D intakes in Study I among adolescent girls without A) and with
B) supplements. Five of the 228 girls did not fill in the FFQ.
Baseline S-25-OHD concentration illustrates more seasonal differences than differences related to
dietary intakes among groups. Vitamin D status in winter best reflects the dietary intake of vitamin
D and its adequacy (Table 9).
Table 9. The distribution of vitamin D status (based on Dawson-Hughes et al. 2005) during winter
months in Studies II-IV.
S-25-OHD, nmol/l Vitamin D status Study II
(%)a
Study III
(%) b
Study IV
(%) c
< 25 Deficient 15 (19.2) 3 (6.1) 0 (0)
25-49.9 Inadequate 54 (69.2) 25 (51) 9 (56.3)
50-79.9 Adequate 8 (10.3) 20 (40.8) 7 (43.7)
? 80 Optimal 1 (1.3) 1 (2.1) 0 (0)
Total 78 (100) 49 (100) 16 (100)
a Included girls that enrolled the study during February and March 2002
b All subjects included during January 2002
c Included men in the placebo group during March 2005
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Wintertime dietary intake of vitamin D and the concentration of 25-OHD correlated positively
among girls and elderly women (Fig. 17) (r = 0.357, p = 0.002 and r = 0.415, p = 0.003,
respectively). In Study IV, this was not tested, because baseline data was collected in October when
results are confounded by solar exposure.
Figure 17. Correlation between S-25-OHD and dietary intake of vitamin D among elderly woman
in Study III (r = 0.415, p = 0.003).
An inverse correlation was found between 25-OHD and PTH in girls and men (Fig. 18 A and B,
respectively), but not in elderly women. In winter, elevated PTH (? 4.1 nmol/l), reflecting
secondary hyperparathyroidism, was observed in 17 (23.9 %) among girls, 17 (34.7 %) among
elderly and 3 (18.8 %) in men. Elevated PTH values were present although subjects were healthy
and their calcium intake was adequate.
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Figure 18. Significant negative correlations between S-25-OHD and S-iPTH were observed among
A) girls (N=228) and B) men (N=52).
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5.2 Seasonal variation in serum 25-OHD, PTH, bone remodelling markers and bone mineral
density (II, IV)
In Study II the mean serum 25-OHD concentration differed between months (ANOVA; p<0.001);
the highest mean concentration was measured in September-October and the lowest in February.
The opposite was observed in S-iPTH concentration, but the difference among months was not
significant in the whole group, (p=0.627), but among early puberty girls (= Tanner stage 2) a
tendency of variation was observed, p=0.069. The monthly mean value for serum 25-OHD and PTH
are shown in Table 10.
Table 10. The monthly mean value for serum 25-OHD and S-iPTH are shown with mean (SD).
a p<0.001 for whole group, p<0.001 for early (=Tanner stage 2, N= 121) p=0.027 for mid puberty
girls (=Tanner Stage 3, N= 75)
b p=0.627, p=0.069, p=0.643
In the whole group of early and midpuberty girls S-OC and U-DPyr concentrations varied among
months after adjustment for age, puberty development, weight, height, physical activity and dietary
intake of calcium (ANCOVA; p=0.062 and p=0.035, respectively) , whereas U-Pyr did not,
p=0.635. After stratification to pubertal stage, only S-OC was found to differed among months
(ANCOVA; p<0.001) among early puberty girls (see original publication fig. 4).
Similarly, the seasonality was seen only among early puberty girls in the BMD of the femur and
lumbar vertebrae. The femoral BMD differed among months (ANCOVA; p=0.047) among early
puberty girls. The BMD in October was 7.6% higher than in March (p<0.008, by contrast). Neither
the femoral BMC nor BA followed the seasonal rhythm (ANCOVA; p=0.229 and p=0.314,
respectively). In the lumbar vertebrae BMD, a trend for seasonal variation was seen (p=0.057),
although the difference between October and March was 7.0 % significant, (contrast; p=0.007). No
seasonality was noted in the lumbar vertebrae BMC or BA (ANCOVA; p=0.168 and p=0.619,
respectively) (see original publication fig. 2 and fig. 3).
Month N S-25-OHD (nmol/l) PTH (pmol/l)
September 35 59.5a  (13.4) 3.18b (1.16)
October 57 54.7 (13.4) 3.30 (0.91)
November 35 41.9 (16.4) 3.35 (1.30)
February 29 37.3 (15.5) 3.41 (0.85)
March 40 38.2 (12.7) 3.56 (1.11)
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In a longitudinal study of men (IV), a seasonal variation in S-25-OHD and PTH concentration was
observed in the placebo group consisting of 16 subjects (repeated measures ANOVA; p<0.001 and
p=0.011, respectively) (Fig. 19 A).
Bone formation marker, S-BALP was maintained in the placebo group of study IV during six
month interval. But for the same men, resorption marker S-TRACP decreased significantly through
winter (repeated measures ANOVA; p<0.05) (Fig. 19B). The difference between November and
April was 7.8%.
In study IV, vBMD was measured from the distal and proximal parts of the radius with pQCT. No
seasonal variation was noted.
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Figure 19. Seasonal variation in a follow-up study of men (IV) in A) S-25-OHD and PTH and B)
bone remodelling markers S-TRACP and S-BALP (N=16).
5.3 Effect of vitamin D supplementation on serum 25-OHD and PTH concentration (I, III, IV)
In supplementation studies (I, III and IV), vitamin D supplementation increased S-25-OHD
concentration dose-dependently (Fig. 20); the higher the dose, the higher the increment in S-25-
OHD concentration. Fig. 21 presents the response of PTH to supplementation.
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Figure 20. Response of S-25-OHD
concentration to vitamin D
supplementation A) adolescent girls, B)
elderly woman and C) men, tested with
repeated measures ANOVA; p<0.001 for
each study. Error bars represent SEM. (?)
placebo, (?) 5µg, (?) 10 µg and (?) 20 µg.
Figure 21. Response of S-iPTH
concentration to vitamin D supplementation
A) adolescent girls, B) elderly woman and C)
men. Only for men, p<0.001. Error bars
represent SEM. (?) placebo, (?) 5µg, (?) 10
µg and (?) 20 µg.
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The dose-response was calculated by dividing the increment in S-25-OHD concentration with a
given dose. Dose-responses were independent of the dosage used. Table 11 summarizes the mean
dose-response (DR) of each study.
Table 11. Dose-responses in Studies I, III and IV presented with means (SDs).
Study Subjects Baseline 25-
OHD, nmol/l
DR, nmol/l/?g
median
95% CI for
mean DR
Correlation between DR
and baseline 25-OHD
I Adolescent
girls
47.6 (17.2) 1.24 (2.51) 1.15 0.81-1.68 -0.606**
III Elderly
women
47.2 (14.7) 1.57 (1.18) 1.32 1.17-1.97 -0.467**
IV Men 67.2 (16.9) 1.54 (1.24) 1.48 1.08-2.00 -0.552**
Mean 1.36 (2.17) 1.23 1.05-1.56
** p<0.001
We observed that S-25-OHD increased more in subjects with a lower initial 25-OHD concentration.
This finding was repeated in each study. In Study III, a plateau in 25-OHD concentration was
reached within 6 weeks with each given dose; dose-responses did not differ between the 6- and 12-
week time-points. In summary, mean dose-responses did not differ between studies, reflecting that
the effect of supplementation over a short period is apparent and that the concentrations reached are
similar to those in longer studies.
Although supplementation did not affect PTH in the whole group of Study I (Fig. 21A), there was a
positive trend present in the autumn cohort (Fig. 22). With 10 ?g of vitamin D, a stable PTH was
maintained throughout the year in adolescent girls. However, PTH was not affected in the short-
term study of elderly women. Positive effects were seen among men; 10 ?g inhibited the seasonal
variation in PTH concentration. For men, total damping down of PTH was obtained with 20 ?g of
vitamin D (Fig. 21C).
The determinants of dose-response were investigated with the linear regression model (Fig. 23).
The model included possible determinants such as age, weight, height, pubertal development stage,
hormone replacement therapy, activity time, intakes of calcium and vitamin D and initial 25-OHD
concentration. Of these, the significant determinants were chosen by a stepwise backward method.
In each study, the final significant determinant was baseline 25-OHD concentration; the ß intercept
was: -0.101 (p<0.001), -0.037 (p=0.030) and 0.058 (p<0.001) for Studies I, III and IV, respectively.
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Figure 22. Response of S-iPTH to supplementation in the autumn cohort of Study I (N=102). The
overall effect was not significant (repeated measures ANOVA; p=0.301), but a trend of difference
was observed at the 6-month time-point (March-April) (p=0.056). Comparison with contrast
indicated that with 10 ?g PTH was lower by 0.723 (0.324) pmol/l (p=0.024) and with 5 ?g lower by
0.576 (0.312) pmol/l (p=0.067) than with placebo.
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Figure 23. Pooled data from Studies I, III and IV (N=197). The association between S-25-OHD and
dose-response was linear as follows y = 4.9 – 0.07 × x. According to this equation, the dose-
response is zero at 70 nmol/l.
5.3.1 Estimation of adequate vitamin D intake (I, III, IV)
Adequate vitamin D intake was estimated in Studies I, III and IV either with the help of dose-
response or based on total vitamin D intakes in subjects with a target 25-OHD concentration. The
goal was to quantify the vitamin D intake that maintains stable 25-OHD throughout the year
(Whiting & Calvo 2005). The target concentration was 60-62 nmol/l, and extrapolations for 80
nmol/l were also performed. In the calculations, the mean dose response was assumed to be 1.4
nmol/l/µg, which is somewhat higher than earlier reports (0.6-1.0 nmol/l/µg) (Heaney et al. 2005).
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In Study I, the mean decrease from baseline in the placebo autumn cohort was 23.0 (12.3) nmol/l,
and according to dose-response an required intake of 16 µg/d would maintain this concentration.
However, the mean total intake among girls in the 10-µg group was 14.5 µg, thus, in practice, this
was adequate. To achieve 80 nmol/l, girls would have needed to increase the 25-OHD concentration
by 32.5 nmol/l; this could have been achieved with roughly 23 µg/d of vitamin D.
Among the elderly in Study III, the mean decrease in the placebo group was 4.5 (13.7) nmol/l,
which would be avoided with an additional intake of 3.2 µg/d, thus increasing the total intake to 13
µg/d. However, the basal mean 25-OHD concentration was 47 nmol/l, hence increasing the S-25-
OHD by 15 nmol/l to 62 nmol/l is achieved with an additional intake of 11 µg/d (total 21 µg/d). We
observed that the total intake of vitamin D among subjects with S-25-OHD concentration around 60
nmol/l was 24 µg/d.
In Study IV, baseline S-25-OHD concentration was 62.4 (14.6) nmol/l. The 25-OHD concentration
decreased 16.8 (11.7) nmol/l in the placebo group until March. According to dose-response, this
would be avoided with an additional intake of vitamin D by 12 µg/d; thus, with basal intake this
sums to 19 µg/d. Similarly, mean total intake among subjects who had maintained stable 25-OHD
(±2) throughout the study was 17 µg/d. Total vitamin D intake among subjects achieving an optimal
vitamin D status (78-82 nmol/l) was 26 µg/d.
5.4 Effect of vitamin D supplementation on bone remodelling markers (I, IV)
In Study I, the resorptive marker, U-DPyr was further decreased by vitamin D supplementation
among adolescent girls (ANOVA; p=0.042) (Fig. 24). The formation marker S-OC was unaffected.
In Study IV, S-BALP decreased in vitamin D supplemented groups whereas it was maintained in
the placebo (ANCOVA; p=0.044) (Fig. 25A). Resorption marker, S-TRACP decreased during the
6-month study, but the change was similar in each group. The ratio of TRACP to BALP was
calculated at baseline and again at 6 months (Fig. 25B) and adjusted for physical activity and
calcium intake. The ratio acted similarly in the groups (P=0.303), but it was determined by changes
in PTH and 25-OHD. In a simple regression model, ?s-iPTH explained 8.8% of the variation in the
TRACP to BALP ratio (P = 0.04), and the standardized ß was -2.108. Likewise, ?s-25-OHD
explained 6.3% of this variation, (P=0.09) and the standardized ß was 0.251.
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Figure 24. Bone remodelling marker changes in adolescent girls presented with bars with SEMs.
The change in U-Dpyr differed among study groups (ANCOVA; p=0.042). The change was larger
in the group receiving 5 µg of vitamin D compared with the placebo group (p=0.013) (marked with
*), but not with the 10-µg group (p=0.304). No difference between the highest group and the
placebo group was noted (p=0.130). The change in OC did not differ among groups (ANCOVA;
p=0.239).
The coupled bone turnover is described with a positive correlation. At baseline, the bone
remodelling markers were positively associated with each other (r = 0.309, p = 0.031) in Study IV.
However, after 6 months, the bone remodelling markers, S-BALP and S-TRACP correlated
positively in the 10 µg- and 20-µg groups, (r = 0.521, P = 0.038 and r = 0.502, p = 0.046,
respectively), but not in the placebo group.
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Figure 25. Bone remodelling markers in men presented with bars and SEMs. Panel A presents the
change in serum formation marker BALP (µg/ml), which differed among groups (ANCOVA;
p=0.044). The effect of vitamin D on BALP was dose-dependent (*p=0.05 for the comparison of
placebo and 10 µg and ** p=0.019 for comparison of placebo and 20 µg). The change in serum
TRACP (U/l) did not vary between groups. Panel B presents the ratio of TRACP to BALP at
baseline and at 6 months. The ratio did not change between groups (p=0.303).
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5.5 Effect of vitamin D supplementation on BMD (I, IV)
With regard to Study I the main results based on IT analysis indicate no effect of vitamin D
supplementation on bone mineral accrual in the femur or the lumbar vertebrae (ANCOVA; p =
0.256 and p = 0.144, respectively) of the adolescent girls. On the other hand, according to CB
results, vitamin D increased dose-dependently bone mineral augmentation both in the femur and the
lumbar spine (Fig. 26) in Study I.
Since BMC augmentation depends on pubertal stage, we tested whether the effect of
supplementation differed between early puberty (Tanner 1 or 2) and mid-puberty (Tanner 3-5)
subgroups. The response to supplementation was similar between subgroups in the femur, but it
differed in the lumbar vertebrae. Among mid-pubertal girls, BMC augmentation in the lumbar
vertebrae was dose-dependent and significant (ANCOVA; p = 0.012), but this was not the case
among early pubertal girls (see original publication I).
The effect of wintertime vitamin D supplementation on vBMD was studied among men (IV) with
pQCT. The change in BMD in TB, Trab and Cort was analysed with ANCOVA, in which the
corresponding ?CSA was used as a covariate. No difference was observed in the ?TB BMD
(p=0.126) or in ?Trab BMD among groups in the distal radius (Fig. 27). Similarly, no change was
present in ?Cort BMD among groups (p=0.175) in the proximal radius.
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Figure 26. Site-specific bone mineral accrual in adolescent girls presented with bars and SEMs.
Panel A indicates the change in femoral BMC in the study groups (ANCOVA; p=0.028). Bone
mineral accrual was 14.3% higher with 5 µg and 17.2% higher with 10 µg than with placebo. Panel
B shows the results of the lumbar vertebrae; note the dose-dependent effect. A significant change
was observed only with the highest dose (ANCOVA; p=0.039), which increased BMC by 12.5%
compared with placebo. P< 0.05 is indicated with * and p<0.01 with **.
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Figure 27. Changes in BMD in total (A), trabecular (B) and cortical (C) bone observed in the study
groups presented with bars and SEMs.
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6. DISCUSSION
6.1 Methodology
6.1.1 Study design and selection bias
Studies I, III and IV were RCTs, which enabled causality to be assessed. A strict follow-up may
interfere with the behaviour of subjects; this is the main bias related to experimental science.
However, this type of study design is thought to give the most reliable evidence of certain causality.
Intention-to-treat (IT) analysis/approach of RCT is preferred in medical sciences. The results of IT
and compliance based (CB) studies are known to differ. For example, both in a secondary
prevention study, RECORD, (Grant et al. 2005) and Women Health Initiative (WHI) study (Jackson
et al. 2006) the effect of vitamin D supplementation together with calcium on fracture prevention
was poor and hardly detectable due to poor compliance, which has been strongly criticized
(Sambrook 2005, Boonen et al. 2007). Likewise, the results of Study I varied according to whether
or not the adolescent girls had taken the supplements; positive effect was more pronounced in
subjects following the protocol than in the whole group. Subjects with poor compliance weakened
the effect of the supplementation on S-25-OHD and BMC augmentation, which justifies
emphasizing the CB results. Furthermore, our primary aim was to define the effect of vitamin D on
bone mineral accrual is Study I. Another issue was to determine the best method to increase the
vitamin D intake in this target group. In addition, the groups were not distorted in basic
characteristics when CB analysis was used.
A cross-sectional study is a type of descriptive research in which subjects and phenomena are more
intact and discrete than in experimental research. Although the results of follow-up and cross-
sectional studies may differ (e.g. Bailey et al. 2000), cross-sectional studies offer some advantages
such as low drop-out rates, less affected behaviour of subjects, and especially in studies exploiting
densitometry measurements, minimal exposure to radiation. However, careful planning of a cross-
sectional study is needed to address the research question.
Selection bias means that participants differ from the typical population; generally volunteers are
considered to be more health-orientated, healthier and better educated than non-participants of the
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target group, which affects generalizability of results. This was the case particularly in studies of
elderly women (III) and men (IV). The use of vitamin D-containing supplements was quite popular
among elderly women in Study III, with one-third taking them. Another marker of health awareness
was the use of hormone replacement therapy; roughly half of the elderly used it. Based on these
assumptions, vitamin D status is likely more impaired among elderly women in general than seen in
Study III, supporting the results of Andersen et al. (2005). This means that the calculated dose-
response in Study III might have been higher due to lower vitamin D status, i.e. typical elderly
women might have responded more prominently to supplementation than seen in our study.
Similarly, men in Study IV had an academic background and were probably more health-aware than
their non-participating peers. In addition, a strict study schedule was thought to be the reason for
drop-outs, as men appeared to be very active during their leisure-time. However, dietary intake of
vitamin D and vitamin D status were in line with the study of Lamberg-Allardt et al. (2006),
suggesting that the men were good representatives of the target group and that the results could be
generalized for healthy men in Finland.
In Study I, schools of adolescent girls were randomly chosen. The girls together with their parents
decided whether they would participate. Over 90% of girls were willing to participate and their
vitamin D status was similar to that of other teenagers in Finland (Lehtonen-Veromaa et al. 1999,
Cheng et al. 2003), implying no selection bias. The results are therefore applicable to this age group
at least in Finland.
6.1.2 Sample size
The number of recruited subjects in each study was based on power calculations assuming 90%
power; however, in the majority of studies, 80% power is adequate to detect an effect (Scheinin
2000). The power and sample size calculations are dependent on the main outcome variable of the
study. Both too small and large sample sizes are unethical. This suggests that pilot studies are
unethical, which is debatable. Small-scale studies are needed to become familiar with a
phenomenon and to learn new methods. Drop-out rates are difficult to predict, although researchers
should anticipate them. In the study of adolescent girls (I) the sample size was based on BMD,
although BMC is considered a better marker of bone mineral accrual (Heaney 2003). In Studies III
and IV, the main outcome variable was 25-OHD, although other variables were measured as well.
Only vBMD results in Study IV lacked the intended power, and thus, these results are somewhat
disputable.
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6.1.3 Methods
An overview of selected methods, including the food frequency questionnaire (FFQ), an analytical
method for detecting serum 25-OHD concentration and methods for detecting BMD, is provided
here. Other methods are discussed elsewhere.
From the nutritional point of view, the estimation of dietary intake of vitamin D is challenging
because natural sources of vitamin D are scarce and the frequency of the consumption of these
sources as well as the portion size vary between populations. Dietary history has been used for the
calculation of vitamin D intake (Willet 1998). The FFQ was validated against food diaries (for a
total of 25 days over a one-year period) of 45 healthy adults. During winter, the dietary intake of
vitamin D by the current FFQ correlates strongly with the corresponding S-25-OHD concentrations
(Studies II-IV) and determines one-fourth of the wintertime 25-OHD (Lamberg-Allardt et al. 2006),
confirming the validity of the FFQ.
The FFQ includes portions of foods that are either rich sources of vitamin D, like salmon, or
sources in frequently use, such as milk. The questionnaire is retrospective, exploring the previous
month. Volumes are generally thought to be more easily remembered by subject than weights
(Willet 1998). Thus, portion sizes could be memorized efficiently with the help of the pictures
included in the FFQ. In addition, more variety exists in frequencies of consumed foods, than in
portion sizes between individuals.
The FFQ tends to overestimate dietary intake of vitamin D compared with a 3- to 4-day food record
at the individual level, but at a group level the difference is less obvious (less than 0.5 µg)
(Lamberg-Allardt et al. 2006). The sources of vitamin D vary among the age groups; since 2003
fortified milk products have been the major source for children and young adults, but fish for older
age groups (Lamberg-Allardt et al. 2006). The 4-day food record may thus be more useful for the
calculation of vitamin D intake among children and young adults, whereas the FFQ may be more
useful for older persons with a more varied diet including such sources as fish, which are not eaten
daily.
According to the literature review, at least six different methods are available to assess S-25-OHD.
Large differences are present between methods and laboratories (Carter et al. 2004). Comparing
literature with results should be done carefully, taking into consideration the methods used and
applying DEQAS standardized 25-OHD values when possible (Dawson-Hughes et al. 2005). In the
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near future, automated analysis will become more common, increasing the repeatability of results.
Issues related to precision will, however, remain. Reference ranges for vitamin D status have
changed over the years, with different cut-off values used in the past, complicating the
comparability of results. The current reference ranges are justified, as they are associated with better
bone health throughout life, as well as with other health outcomes as described elsewhere (Bischoff-
Ferrari et al. 2006). However, only a fraction of the Finnish population reached an optimal vitamin
D status in 2004 (Lamberg-Allardt et al. 2006).
Finally, DXA-derived BMD is size-dependent and reflects bone mass rather than bone density.
However, in growth studies BMC might characterise bone mass accrual better than BMD (Heaney
2003), but it is not utilized as much as it could be because it strongly depends on bone size as well.
Among adolescent girls, we were intrigued by the BMC increasing due to an increase in bone size
as bone grew, as well as to enhanced mineralization as a result of vitamin D supplementation. To
investigate bone mineral accrual, we needed to adjust the increase in BMC by the increase in bone
size, assuming that the growth was similar in groups, which it pretty much was, but the anabolic
effect of vitamin D was neglected. Vitamin D-supplemented girls gained more weight during the
study, which could be due to higher mineral accrual or to extra lean mass, probably muscle mass.
In Study I, we could not conclude, whether vitamin D induced mineralization in Trab or Cort
compartment; here pQCT is more suitable than DXA. However, the limitation of pQCT is that only
peripheral sites can be measured (Specker & Schoenau 2005), and in peripheral sites, changes are
believed to occur over a longer period than in central sites (Szulc et al. 2003). DXA and pQCT
measurements are highly biased by the user, by positioning of the subject and by performing the
analysis similarly, etc. Fairly small changes become undetectable if these confounding factors are
not taken into account. Duplicate measurements of a small group of subject will clarify the
repeatability issue of results.
6.2 Vitamin D status and intake among target groups
Mean baseline 25-OHD concentration among adolescent girls in Study I was 47.6 (17.2) nmol/l
over a 6-month period. This concentration could be regarded as illustrating the average vitamin D
status among 11- to 12-year-old Finnish girls in 2001-2002. However, this semiannual mean value
includes a seasonal variation. Between November and March the mean 25-OHD was lower than 50
nmol/l, which is considered the cut-off value for inadequate vitamin D status (Dawson-Hughes et al.
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2005, Rizzoli et al. 2008). Before November, the total vitamin D intake from the diet and sun
exposure was adequate for these adolescent girls. Most studies that examine vitamin D status are
performed in the winter. When comparing results of the lowest is reasonable, but the vitamin D
status in the summer completes the picture.
Among adolescent girls, the mean 25-OHD during winter was 36.0 (13.7) nmol/l, which agrees with
other studies for this age group (Lehtonen-Veromaa et al. 1999, Outila et al. 2001). We observed
that 19% of adolescent girls studied during February and March were vitamin D-deficient (S-25-
OHD<25 nmol/l) and 69% had an inadequate vitamin D status, both of these conditions being
characterized by increased PTH concentration, which is harmful for the skeleton in the long run. A
higher (32-37%) prevalence of vitamin D deficiency has been reported among Finnish adolescent
girls (Cheng et al. 2003, Andersen et al. 2005), as has a lower (13%) prevalence (Lehtonen-
Veromaa et al. 1999, Outila et al. 2001). Of these studies, those dated 2003 or earlier have used
Incstar Corporation Stillwater RIA for assessing 25-OHD, as opposed to HPLC, which would have
overestimated 25-OHD about 5 % compared with the RIA, thus explaining part of the differences.
The vitamin D status of adolescent girls has been quite similar across Europe (Poland, Irland,
Denmark, Finland) (Andersen et al. 2005) as well as in North America (Gordon et al. 2004,
Harkness et al. 2005). The median dietary intake of vitamin D calculated with FFQ was 4.5 (4.0) µg
among adolescent girls, which agrees with the FFQ-assessed vitamin D intake among Finnish 9- to
15-year-old and 12- to 13-year-old girls (Lehtonen-Veromaa et al.1999, Outila et al. 2001,
Andersen et al. 2005). Lower intakes (3.0-3.7 µg) have been observed in the same age group with a
4-day food record (Cheng et al. 2003).
The ambulatory elderly women in Study III had a mean 25-OHD concentration of 47.2 (14.7)
nmol/l during winter, reflecting substantially better vitamin D status than in adolescent girls. In fact,
only 6% of elderly women were vitamin D-deficient, in line with another study (Nurmi et al. 2005)
(based on RIA method). The low prevalence of vitamin D deficiency partly could be due to bias
related to the selection of subjects, as discussed above, as Andersen et al. (2005) reported the
prevalence of vitamin D deficiency to be 17% among elderly Finnish women. The elderly in
nursing homes and in long-term care commonly suffer from vitamin D deficiency (Lamberg-Allardt
1984, Suominen et al. 2004), but the ambulatory elderly are aware of the risk and include
supplements in their diet accordingly. Total vitamin D intake among the elderly women was 9.2
(5.7) µg/day, which nevertheless is a somewhat lower than recommended for this age group (Nordic
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Council of Ministry 2004), but similar to figures reported in other studies (Lamberg-Allardt et al.
2006).
At enrolment (in October 2004), the mean 25-OHD concentration was 67.2 (16.9) nmol/l among
healthy men in Study IV. In January 2005, the mean 25-OHD concentration dropped below 50
nmol/l. No cases of vitamin D deficiency existed, but 56% of unsupplemented men had inadequate
vitamin D status in winter. This differs from the results of Välimäki et al. (2007), who reported
vitamin D deficiency (S-25-OHD below 20 nmol/l) in 29% and S-25-OHD between 20 and 37.5
nmol/l in 44% of young men. In their study, both the RIA and HPLC methods for analysing 25-
OHD were used, but there was no standardization of results (variation in result -6% to +7%) and the
cut-offs used have been replaced with newer ones. Our results do, however, agree with those of
Lamberg-Allardt et al. (2006), who showed that the median 25-OHD concentration among 27- to
35-year-old men was 44 nmol/l and among 36- to 60-year-old men 52 nmol/l. The dietary intake
among men in study IV was 6.6 (5.2) µg a day, which is in line with Lamberg-Allardt et al. 2006.
In general, the use of vitamin D-containing supplements was beneficial in all target groups. Without
supplement users, the median and mean values for vitamin D intake were even lower (see Study I).
Thus, vitamin D supplements are recommended, when an individual does not consume fortified
milk over 500 ml a day, consume spreads on bread and in cooking or eat fish at least twice a week.
In summary, vitamin D intake and vitamin D status among adolescent girls were both inadequate.
The situation was better among elderly women and among men, as reflected by their intake and
vitamin D status. In 2003, the fortification of liquid milk started, and this improved vitamin D
intake and status in the Finnish population (Lamberg-Allardt et al. 2006). The currently
recommended adequate intake for vitamin D is 7.5 µg, which is an improvement but likely still too
low for these age groups.
6.3 Effect of seasonal variation in vitamin D status on bone (re)modelling and BMD
Seasonal variation was illustrated in 25-OHD and PTH concentration both in the cross-sectional
study of adolescent girls and in the longitudinal study of men, is consistent with earlier studies
(Lamberg-Allardt 1984, Rozen et al. 1994, Woitge et al. 2001, Carnevale et al. 2001, Meier et al.
2004). Typically, circannual variation is observed in S-25-OHD, but less often in PTH or calcitriol
(Woitge et al. 2000) due to sampling because PTH has a diurnal rhythm and calcitriol changes only
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in rare cases such as in severe vitamin D deficiency or menopause (e.g. Heikkinen et al. 1997). In
addition, the biological half-life of calcitriol is relatively short (12-18 h), and it has a quick response
to PTH (Brown et al. 1999).
The impact of seasonal variation on bone is studied by following bone remodelling markers (Rozen
et al. 1994, Woitge et al. 2000, Lehtonen-Veromaa et al. 2002) and BMD (Bergstralh et al. 1990,
Dawson-Hughes & Harris 1993, Rozen et al. 1994, Meier et al. 2004). Error sources related to
cross-sectional studies might overestimate the effect on bone or bone turnover (Woitge et al. 1998,
Seibel et al. 2004). However, in Study II on adolescent girls, the group was homogenous with
regard to age, weight, height and sexual maturation, the main potential sources of bias related to
cross-sectional studies. Longitudinal follow-up studies have utilized DXA in BMD measurement,
but to our knowledge, pQCT, which was exploited in Study IV, has not been used for this purpose
before.
Previously bone resorption was suggested to increase and bone formation to decrease during winter,
and vice versa during summer (Rozen et al. 1994). Currently, bone turnover is shown to accelerate
during winter, meaning that more bone is resorbed than formed in winter, however, the bone
turnover seems to recover to the initial level in summer (Meier et al. 2004). This explains why
BMD decreases during winter, but does not reach to the initial value during the following summer
(Meier et al. 2004, Seibel et al. 2004). In the cross-sectional study of adolescent girls (II), the bone
formation marker osteocalcin was lower in winter, but the resorption markers were similar over
months. Bone resorption markers are thought to be more sensitive to dietary manipulation than
formation markers (Borderie et al. 2001), but among these rapidly growing early and mid-pubertal
girls the balance in bone remodelling/modelling is placed on the formation site, which might
explain our observations. In addition, a positive association between vitamin D status and formative
markers has been described by others (Woitge et al. 2000, Lehtonen-Veromaa et al. 2002). In regard
to resorption markers, the individual variation in bone remodelling marker levels has been
demonstrated to be very high at puberty, and one-time specimen is thus not informative in a cross-
sectional study (Watts 1999, Borderie et al. 2001).
In the prospective study of men (IV), the effect of season was observed in the placebo group; the
resorption marker S-TRACP decreased significantly, on average 7.8% from November to April,
while the S-BALP concentration was maintained. Whether the change in TRACP is clinically
relevant is unclear. Firstly, the intra-CV% for this assay was 4%. However, the ratio or an index
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applying both remodelling markers might be more informative than an individual marker (Eastell et
al. 1993). The ratio of TRACP to BALP decreased somewhat during the 6-month period, which
shows that the bone turnover rate slows down when vitamin D status is impaired. Previous studies
(e.g. Woitge et al. 2000, Meier et al. 2004) have proposed that no seasonal variation exists in bone
turnover among men. In addition, bone remodelling in general is more stable among men than
women (Seeman 2003b). Remodelling is vital for normal bone renewal (Parfitt 2003). Vitamin D
may act as a coupling factor in the remodelling process (Eastell et al. 1993, Gurlek et al. 2002),
affecting both formation and resorption, which is supported by our results.
The results concerning the BMD in the cross-sectional study (II) suggest, that season contributed to
7.5-8.2% of the change in the BMD of the lumbar spine and femur, respectively, in early pubertal
girls. The change is higher than reported in prospective studies of healthy adults (1-2%) (Bergstralh
et al. 1990, Meier et al. 2004), but similar to that in the cross-sectional studies of the elderly (Rapuri
et al. 2002, Bhattoa et al. 2004). Interestingly, the early pubertal girls (II) seemed to be more
sensitive to seasonal rhythm than their mid-pubertal peers possibly due to sex hormones that acted
on the vitamin D-PTH axis. In fact, there is increasing evidence that oestrogens influence bone
mineral accrual and maintenance (e.g. Rizzoli et al. 2001), and this could explain why the bones of
early pubertal girls (before menarche) and postmenopausal women are more susceptible to changes
of vitamin D status.
Men with higher vitamin D intake from the diet and with more stable bone turnover are proposed
not to be exposed to seasonal variation like women (Carnevale et al. 2001, Seibel et al. 2004). In
fact, previous studies that have reported seasonal variation in areal BMD (Bergstrahl et al. 1990,
Dawson-Hughes et al. 1991, Rozen et al. 1994, Meier et al. 2004) included mostly female subjects.
The volumetric BMD from the non-dominant radius, considered a clinically relevant site in the
study of men (IV) did not indicate any seasonal variation. However, the distribution of volumetric
BMD from a certain site is much narrower than the distribution of areal BMD from the same site
(Riggs et al. 2004). Inadequate vitamin D status affects bone mass; with DXA, this is marked as
decreased BMC and BMD, whereas with pQCT it is expected to be observed firstly and
predominantly in Trab BMD (e.g. Rüegsegger et al. 1995) and after a time, in the Cort BMD, as the
chronically elevated PTH increases Cort resorption, especially at the outer surface of bone (Adami
et al. 1998, Bilezikian 2003). During impaired vitamin D status, the mineralization of bone
decreases, but how soon does the bone compensate for this by rearranging and replacing the
remaining minerals - thus increasing its diameter to aid in maintaining bone strength (van der
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Meulen 2001). Longer prospective studies are needed to fill in the gaps in our knowledge of
seasonal variation and bone health.
The discrepancies between the data on BMD and remodelling markers are likely explained by bone
remodelling markers reflecting the situation in the central skeleton (Parfitt 2003, Szulc et al. 2003),
whereas the vBMD was measured from a peripheral site. It is believed that seasonal variation of
BMD should be avoided as it could complicate bone mass accrual during puberty (Lehtonen-
Veromaa et al. 2002). In addition to icy and snowy weather conditions, lowered vitamin D status
during winter might explain why Scandinavian countries have a higher incidence of osteoporotic
fractures than other countries in Europe (Epos 2002, Bischoff-Ferrari & Dawson-Hughes 2007).
One approach to estimate adequate vitamin D intake for a target group is to find the dose that
maintains stable vitamin D status and PTH concentration throughout winter (Heaney et al. 2003a,
Whiting & Calvo 2005).
6.4 Effect of vitamin D supplementation on serum 25-OHD and PTH
Vitamin D supplementation increased serum 25-OHD concentrations dose-dependently in Studies I,
III and IV. Calculated dose-responses (nmol/l/µg) enable us to compare results from different
studies and to extrapolate the dose needed to reach a certain 25-OHD concentration. The mean
dose-response did not differ among studies, indicating that the short-term study was long
sufficiently to attain the effect described in longer studies. The vitamin D pool in the body has been
shown to turn over every 42 days (Heaney et al. 2003a); our results are consistent with this, as a
plateau in serum 25-OHD concentration was reached in 6 weeks in elderly women. However, this
should not be confused with the biological half-life of the 25-OHD molecule, which could vary
between 1 and 3 months depends on the circulating levels of PTH and factors regulating PTH
secretion, calcium and phosphorus intake and other hormones (Brown et al. 1999).
The mean dose-response was 1.36 (2.17) nmol/l/µg depending on the initial 25-OHD concentration.
In the pooled data, these showed a strong linear inverse association, which has been reported by
others as well (e.g. Heaney 2005). Thus, when the baseline 25-OHD concentration exceeds 70
nmol/l, supplementation of 5-20 µg does not increase it any further. This might indicate that the
initial hydroxylation step of vitamin D (25-hydroxylation) that takes place in the liver occurs
predominantly without control when the initial 25-OHD concentration is low, but is down-regulated
when the initial 25-OHD is higher. Some studies have shown that 1,25(OH)2-vitamin D could
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down-regulate liver 25-hydroxylases (e.g. Bell et al. 1985), at least intermittently. However, we
suggest that increasing 25-OHD could activate other possible routes of the metabolism, as also
proposed by Willnow & Nukjaer (2005), although other explanations, including degradation of 25-
OHD have been tendered. Weight has been reported to modify the dose-response in a few studies
(Heaney et al. 2003a), but no association was noted with dose-response in linear regression models
in Studies I, III or IV when data were analysed separately or pooled.
A plateau in the 25-OHD concentration noted in the study of elderly women (III) illustrates that
vitamin D metabolism reaches a balance at certain dosages. Intake and utilization are thus balanced,
or beyond a certain threshold, consumed vitamin D is stored rather than circulated in the blood.
However, continuous long-term use of supplements is not recommended, as this could lead to
accumulation of vitamin D in the body (Vieth 1999), seen as a further increase in circulating 25-
OHD concentration after the first plateau. To avoid this, regular monitoring of 25-OHD
concentration is advisable if large dosages are used. The upper limits for intake of 25 µg for
children under 11 years and 50 µg for individuals older than 11 years (Scientific committee on Food
2002) thus seem reasonable.
In the study of adolescent girls (I), 25-OHD increased with supplementation of 10 µg to 60 nmol/l,
which is lower than defined as optimal (Dawson-Hughes et al. 2005); this nevertheless had a
significant effect on bone mineral accrual and maintained stable PTH throughout the year.
However, with the HPLC method, the bias is 5% (Carter et al. 2004). The concentration is believed
to be underestimated, the standardized 25-OHD concentration would thus be 63 nmol/l. Moreover,
the vitamin D requirement may be modified by calcium intake (Lips 2004). In addition, the review
of Dawson-Hughes and colleagues (2005) did include only one study concerning adolescents
(Lehtonen-Veromaa et al. 2002), which was not successfully performed. In their study, 13- to 15-
year-old girls were supplemented with vitamin D2 and they reached a 25-OHD concentration of 41
nmol/l (analysed by RIA, which has a poor sensitivity for 25-OHD2) (Lehtonen-Veromaa et al.
2002). In light of these data, we suggest that S-25-OHD concentration of 60 nmol/l is beneficial for
bone in conditions such as those in Finland with a high habitual intake of calcium. The total intake
among adolescents in the highest supplemented group was on average 14.5 µg (10 µg from
supplements and 4.5 µg from the diet), and this seems adequate for this age group.
In the study of the elderly (III), the total intakes in each 25-OHD category (10-nmol/l categories)
were calculated. A concentration of 40-49.9 nmol/l, which has previously been considered
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sufficient by McKenna & Freaney (1998) and Need et al. (2000), is maintained with 17 µg, but a
concentration above 60 nmol/l, which is typical during summer in Finland, is achieved with 24 µg.
In the study of healthy men (IV), optimal 25-OHD concentration was achieved with
supplementation doses of both 10 µg and 20 µg a day, but the latter dose further suppressed the
PTH from baseline, which was not an objective of the study. A stable PTH was maintained with 10
µg of vitamin D. Thus, the total intake of vitamin D required for healthy men is about 17 µg (10
µg+6.6 µg).
6.5 Effect of vitamin D supplementation on bone
Vitamin D intervention studies have not been carried out in adolescent girls in a RCT setting with a
clinically relevant BMD as an outcome variable. Intervention trials with vitamin D alone on the
growing and adult skeleton are required.
The results of the study of adolescent girls (I), especially those of BMD and change in BMC, were
highly depended on compliance. Although the main result of the RCT, with all subjects included,
showed no effect of vitamin D on bone mineral accrual either in the femur or in the lumbar spine,
we performed the CB analysis to focus on the compliant subjects. There were two logical reasons
why the CB was based on pill counts in Study I. Girls were advised to take 28 pills each month for
12 months. The total amount of pills consumed was thus 336. Those following the protocol had
consumed at least 80% of the pills (269 pills). With this method, we excluded those who had not
taken pills for over 2.4 months. In fact, there is a correlation between taken pills and the ?s-25-
OHD in both supplemented groups (r=0.212, p=0.015). In addition, the half-life of s-25-OHD
molecule is 2-3 months, and unequal distribution of oral vitamin D could be seen in lowered S-25-
OHD concentrations. The study was double-blinded, meaning that subjects with poor adherence in
the placebo group were excluded as well. However, the exclusion seemed to affect more the mean
values of BMD and BMC in the placebo group than those in the vitamin D-supplemented groups
probably because more subjects were excluded, and the excluded girls seemed to be somewhat (but
not significantly) taller and heavier in the placebo group than in the other groups. These may partly
explain the observed decrease in the BMC and BMD values. However, the exclusion of the subjects
did not distort the baseline characteristics in the groups.
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Finally, the changes in BMC were tested with ANCOVA using as covariates changes in BA
(Prentice et al. 1994, Carter et al. 2001, Lehtonen-Veromaa et al. 2002, Mølgaard et al. 2004),
weight and Tanner stage, as these may confound the interpretation. For example, an increase in
BMC may be neutralised by an increase in BA, although vitamin D is expected to increase BMC by
enhancing mineralization. All girls were growing and their bone size increasing, so using ?BA as a
covariate adjusted the growth and allowed focusing on the increase in BMC. Similarly, increases
both in weight and the Tanner stage induces BMC gain, which justifies using these in the model.
Choosing different covariates in the model may influence the result. It is recommended to use
baseline values as covariates in such a model (Vickers & Altman 2001). Our model did not initially
include baseline values. Further analyses showed that they only had a minor effect on the results
(data not shown).
CB results show that vitamin D supplementation increased BMC augmentation dose-dependently
both in the femur and in the lumbar spine in adolescent girls (I). Retention in the femur region was
14.3% and 17.2% higher in groups receiving either 5 ?g or 10 ?g of vitamin D, respectively, than in
the placebo group. Similar results were demonstrated in the lumbar vertebra, albeit only the highest
dose increased BMC augmentation significantly in the whole group. Our results agree with previous
studies in which vitamin D promotes bone mineral accretion in adolescent girls (Lehtonen-Veromaa
et al. 2002, Moyer-Mileur et al. 2003). In addition, our results suggest that the effect of threshold
nutrients on bone mineral augmentation during growth is vaster than during other phases of life
(Heaney et al. 2000). A year is a relatively short period of time when BMD or BMC is the main
outcome; adult bone turnover varies between 1 and 2% annually, which is the same variance as in
the repeatability of DXA. The least-significant change in DXA studies is about 3 %. However,
during puberty (before menarche) and after menopause, bone turnover is accelerated (accrual or
loss) and the impact of vitamin D is more distinct. Puberty is an extremely sensitive growth period
during which retention occurs maximally, and any nutrient deficiency, such as calcium or vitamin D
deficiency, could hinder the PBM accumulation (Bailey et al. 2000). Eating disorders and unhealthy
food habits during puberty should be handled extra carefully as their impact on bone is greater than
during any other time of life (Specker & Schoenau 2005).
Spine growth accelerates at puberty (Bass et al. 1999). This could be the reason why mid-pubertal
girls in Study I responded more efficiently to vitamin D supplementation than early pubertal girls
when considering the results of lumbar vertebra. In fact, among early pubertal girls, BMC accrual at
the lumbar vertebra did not differ among study groups. Tempo of pubertal growth might be
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interesting factor to consider as teens with a high growth speed tend to achieve lower PBM than
teens with a longer growth spurt (Bass et al. 1999). Nutrients and genes are the main determinants
of growth tempo. Among undernourished or severely obese children, the tempo of growth changes
(Marshall & Tanner 1969, Specker & Schoenau 2005). Both premature growth and delayed pubertal
growth influence the adult stature by decreasing the predicted adult height (Dunkel 2000).
Vitamin D intervention studies have been carried out mainly in the elderly (Ooms et al. 1995,
Dawson-Hughes et al. 1997, Trivedi et al. 2003), and the focus has been on the prevention of bone
loss and adjacent bone fractures, in other words, the focus is on secondary and tertiary prevention of
osteoporosis. Sometimes the results of interventions in the elderly have been discordant (Lips et al.
1996, Hunter et al 2000, Patel et al. 2001, Grant et al. 2005) as mentioned earlier. In some studies
where positive effects on bone health were marked, calcium supplementation was also included
(Dawson-Hughes et al. 1995, Chapuy et al. 2002), reinforcing the traditional concept that the effect
of vitamin D on bone is mediated through calcium balance, as vitamin D-deficient persons with
adequate calcium intake will benefit from vitamin D monotherapy. A meta-analysis by Tang et al.
(2007) concluded that the best therapeutic effect for persons over 60 years is attained with at least
1200 mg of calcium and 20 µg of vitamin D for decreasing fracture risk and BMD changes.
However, the effect of vitamin D might act via influence through muscle tissues (e.g. Bishoff-
Ferrari et al. 2004c), as vitamin D supplementation have been shown to improve the maintenance
and performance of muscles. Myopathy is frequently related to osteomalacia (Parfitt 2003). In
addition, immobilized elderly persons have a higher risk for vitamin D deficiency than more
ambulatory seniors. According to this muscle theory, vitamin D deficiency might have caused the
immobilization rather than vice versa.
In Study IV with healthy men, vBMD measurements were repeated after 6 months, which may have
been a too short follow-up. However, we considered this justified since if seasonal variation is
present in the peripheral skeleton, it should be detectable within 6 months when the number of
subjects is adequate. We calculated retrospectively the power analysis with 80 %, that a sample size
of 37 in each group would have been required to detect a clinically relevant 2 % change in Cort
BMD. Our initial sample size in Study IV based on 25-OHD was unfortunately not large enough for
vBMD. The effect of vitamin D on radius vBMD in men remains unsolved. The study of Moyer-
Mileur et al. (2003) with preadolescent girls indicated that calcium and vitamin D therapy increased
Trab vBMD in the distal tibia, but to our knowledge, there are no other studies that have used pQCT
for this purpose. In some studies with male subjects (Szulc et al. 2003, Välimäki et al. 2004), a
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positive association between 25-OHD and areal BMD was reported, and a similar association was
observed among young females (Outila et al. 2001).
Interestingly, vitamin D supplementation had no effect on the bone formation marker osteocalcin;
this concentration decreased slightly among adolescent girls during the Study I, as is expected to
during normal puberty (Bass et al. 1999, Fares et al. 2003). The U-Pyr concentration, which reflects
bone resorption, decreased more in the vitamin D-supplemented groups than in the placebo group,
but the effect was not dose-dependent. This implies that supplemental vitamin D has antiresorptive
properties that spare bone mineral. We assume that these functions are due to improved calcium
balance (Heaney et al. 2000, Prentice 2004), as calcium has been shown to decrease bone resorption
(Wastney et al. 2000). Our results conflict with those of Schou and coworkers (2003), who reported
that vitamin D supplementation, had no effect on bone remodelling markers in 20 children aged 6-
14 years. However, the number of subjects in the study of Schou et al. (2003) was small and the
results were not controlled for individual variation, e.g. age and pubertal development, which could
have obscured the effect. Adequate vitamin D status has been associated with decreased bone
resorption markers in other studies (Lehtonen-Veromaa et al. 2002, Cheng et al. 2003), and in
vitamin D deficiency all biochemical markers of bone turnover are known to be elevated (Scariano
et al. 1995).
Bone remodelling markers might act differently in men than in women due to different bone
turnover rates (Woitge et al. 2000). Resorption and formation are strongly coupled in bone
remodelling (Parfitt 1989, Woitge et al. 2000), which we noted at baseline in Study IV. However,
vitamin D supplementation of 10 µg and 20 µg significantly decreased S-BALP concentration by
9.1% and 11.3%, respectively. BALP is generally thought to indicate the viability of osteoblasts,
but it could also be considered a marker of bone turnover (Avbersek-Luznik et al. 2007). The
generalization of bone matrix parallels the maturation of osteoblasts, thus decreasing BALP (Parfitt
2003). Among vitamin D-deficient children, the BALP concentration is typically elevated; the bone
formation rate is high (Wharton & Bishop 2003), and the concentration of BALP decreases as
mineralization occurs (Scariano et al. 1995, Ros et al. 2005). Another possible explanation is that
the total bone turnover rate decelerated, as PTH was lower in vitamin D-supplemented groups than
in the placebo. Nevertheless, PTH within a normal range is required for normal bone turnover (e.g.
Parfitt 1989, Gabet et al. 2006). With 10 µg of vitamin D, a stable, normal PTH concentration was
maintained throughout the study.
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The concentration of TRACP decreased in all groups in a similar way. The results of TRACP are
discordant with earlier studies in which bone resorption increased during winter (Woitge et al. 2000,
Meier et al. 2004). However, the basal intake of men was nearly 7 µg, and men in the placebo group
did not become vitamin D-deficient, only vitamin D-inadequate. Thus the drop in 25-OHD was not
high sufficiently to induce bone resorption among men, who generally have more stable bone
turnover than women (Seeman 2003b). Furthermore, the ratio or an index applying both
remodelling markers might be more informative than individual markers (Eastell et al. 1993). Our
results support this, as the ratio of TRACP to BALP was shown to vary according to PTH and 25-
OHD. The ratio was kept stable with 20 µg, while it decreased somewhat in other groups during the
6-months of winter. In addition, a strong correlation was observed between TRACP and BALP at
the beginning of the study, which also illustrates coupling. In the vitamin D-supplemented groups,
bone turnover remained coupled at the end of the study, supporting the coupling effect of vitamin D
(Gurlek et al. 2002).
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7. SUMMARY AND CONCLUSIONS
Novel findings in this thesis were related to vitamin D and bone metabolism. Firstly, a seasonal
variation of calcitropic hormones was indicated to affect bone metabolism in healthy men, and in a
cross-sectional study of adolescent girls, BMD was observed to differ among months, reflecting
seasonal variation. Secondly, in a randomized placebo-controlled trial, vitamin D was shown to
enhance bone mineral accretion in adolescent girls, which seemed to occur dose-dependently and by
decreasing bone resorption, but these results were dependent on compliance. Finally, dose-
responses obtained in each study enable to calculate vitamin D intakes required to achieve a certain
S-25-OHD concentration.
Specific findings in each study were:
§ The main analysis did not support that vitamin D supplementation had a beneficial effect on
bone mineral accumulation in the adolescent girls. However, confining the analyses only to
those subjects that had at least a 80 % compliance rate, the results showed that 10 µg of vitamin
D increased BMC by 17.5% in the femur, and by 12.5% in the lumbar spine compared to the
placebo. This effect was mediated by a decrease in bone resorption, possibly through an
improved calcium balance. The positive results depended on the compliance of the subjects,
indicating that supplementation may not be the optimal means to increase vitamin D intake
among adolescent girls. However, increased vitamin D intake had clinically relevant effect on
bone mineral accrual in adolescent girls with habitually high dietary intake of calcium. Changes
that occur during growth period in bone mineralization are possibly maintained after the
cessation of the supplementation, suggesting that puberty is optimal timing for enhancing bone
mineral accrual.
§ In a cross-sectional study of adolescent girls, calcitropic hormones, BMD and bone formation
marker differed among months reflecting seasonal variation. Early pubertal girls were more
pronounced to this variation than mid-pubertal girls, proposing that estrogens may modify the
effect of calcitropic hormones on bone metabolism. Although no causality could be pointed out
in cross-sectional study, seasonal variation is speculated to complicate PBM attainment during
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growth, and thus, increase the risk of osteoporosis later in life. With vitamin D intake of 15 µg,
this variation could be avoided in adolescent girls.
§ In the elderly study, a plateau in S-25-OHD concentration was achieved in six weeks.
Calculated mean dose-response was 1.36 nmol/l/µg, which enables one to estimate the effect of
supplementation on S-25-OHD. Based on this, we estimated that ambulatory elderly require on
average 18 µg a day to maintain adequate vitamin D status (above 50 nmol/l) during winter. To
reach 60 nmol/l, which is a typical 25-OHD concentration in summer, the total intake should be
approximately 24 µg. Three months study was not long enough to affect PTH among the
elderly. Previously, the elderly were shown to require higher vitamin D dosages to suppress
PTH; however, cases with primary hyperparathyroidism were not ruled out.
§ Vitamin D supplementation over a period of six months did not reveal (statistically) significant
differences in radial volumetric BMD in healthy men, possibly due to the low number of
subjects. However, the calcitropic hormones and the bone remodelling markers responded to
supplementation. Bone turnover seemed to become uncoupled in the placebo group, which is
considered harmful in the long run. With 18 µg of vitamin D, most of the changes were
reversed, but more observations are required to confirm the effects of vitamin D
supplementation on bone health in men.
The main objective of this thesis was to define an adequate vitamin D intake for healthy adolescent
girls, men and elderly women. An adequate intake of vitamin D maintains stable S-25-OHD and
PTH concentrations, and thus, avoids seasonal changes in bone turnover, which is considered
beneficial for bone health. Based on these studies, adequate vitamin D intake varies between 15 µg
and 24 µg per day for the target groups. A question, arising from the results, is how these adequate
vitamin D intakes are achieved? Daily dietary intake of 10 µg is achieved by following current
dietary guidelines, but to increase the intake beyond that either supplements or new tailor made
products are needed to keep the diet as balanced as possible.
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